0001477932-22-003316.txt : 20220516 0001477932-22-003316.hdr.sgml : 20220516 20220513174934 ACCESSION NUMBER: 0001477932-22-003316 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 43 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220516 DATE AS OF CHANGE: 20220513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: United Health Products, Inc. CENTRAL INDEX KEY: 0001096938 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 841517723 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-27781 FILM NUMBER: 22924310 BUSINESS ADDRESS: STREET 1: 10624 S. EASTERN AVE STREET 2: STE. A209 CITY: HENDERSON STATE: NV ZIP: 89052 BUSINESS PHONE: (877) 358-3444 MAIL ADDRESS: STREET 1: 10624 S. EASTERN AVE STREET 2: STE. A209 CITY: HENDERSON STATE: NV ZIP: 89052 FORMER COMPANY: FORMER CONFORMED NAME: United EcoEnergy Corp. DATE OF NAME CHANGE: 20060224 FORMER COMPANY: FORMER CONFORMED NAME: MNS EAGLE EQUITY GROUP III INC DATE OF NAME CHANGE: 19991019 10-Q 1 ueec_10q.htm FORM 10-Q ueec_10q.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2022

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ____________ to ____________

 

Commission file number: 000-27781

 

UNITED HEALTH PRODUCTS, INC.

(Exact name of Company as specified in its charter)

 

Nevada

 

84-1517723

(State or other jurisdiction

of incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

10624 S. Eastern Ave., Suite A209

Henderson, NV

 

89052

(Address of Company’s principal executive offices)

 

(Zip Code)

 

(877) 358-3444

(Company’s telephone number, including area code)

 

None

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12 (b) of the Act: None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by checkmark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the 12 preceding months (or such shorter period that the registrant was required to submit such file). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

Non-accelerated Filer

Smaller reporting company

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No ☒

 

The number of shares issued and outstanding of the Registrant’s Common Stock, as of May 10, 2022 was 230,127,509

 

 

 

 

UNITED HEALTH PRODUCTS, INC.

 

FORM 10-Q QUARTERLY REPORT

 

TABLE OF CONTENTS

 

 

PAGE

 

PART I. FINANCIAL INFORMATION

 

Item 1.

Financial Statements (Unaudited)

 

Condensed Balance Sheets as of March 31, 2022 (unaudited) and December 31, 2021

3

 

Condensed Statements of Operations for the Three Months Ended March 31, 2022 and March 31, 2021 (unaudited)

4

 

Condensed Statement of Stockholders’ Deficiency for the Three Months Ended March 31, 2022 and March 31, 2021 (unaudited)

 

5

 

 

 

 

 

 

 

Condensed Statements of Cash Flows for the Three Months Ended March 31, 2022 and March 31, 2021 (unaudited)

6

 

Notes to Condensed Financial Statements (unaudited)

7

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

15

 

Item 3.

Quantitative and Qualitative Disclosures

21

 

Item 4.

Controls and Procedures

21

 

PART II. OTHER INFORMATION

 

Item 1.

Legal Proceedings

22

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

22

 

Item 3.

Defaults Upon Senior Securities

22

 

Item 4.

Mine Safety Disclosures

22

 

Item 5.

Other Information

22

 

Item 6.

Exhibits and Reports on Form 8-K

23

 

SIGNATURES

 

25

 

 
2

Table Of Contents

 

UNITED HEALTH PRODUCTS, INC.

Condensed Balance Sheets

 

 

 

March 31,

 

 

December 31,

 

 

 

2022

 

 

2021

 

 

 

(Unaudited)

 

 

 

 

ASSETS

 

Current Assets

 

 

 

 

 

 

Cash and Cash Equivalents

 

$32,955

 

 

$21,799

 

Prepaid and other current assets

 

 

5,000

 

 

 

5,000

 

Total current assets

 

 

37,955

 

 

 

26,799

 

 

 

 

 

 

 

 

 

 

Patents, net

 

 

39,488

 

 

 

-

 

 

 

 

 

 

 

 

 

 

TOTAL ASSETS

 

$77,443

 

 

$26,799

 

 

 

 

 

 

 

 

 

 

Current Liabilities

 

 

 

 

 

 

 

 

Accounts payable and accrued expenses

 

$1,014,412

 

 

$826,486

 

Accrued liabilities - related parties

 

 

138,616

 

 

 

3,207

 

Accrued litigation settlement

 

 

450,000

 

 

 

120,000

 

Promissory note payable

 

 

85,080

 

 

 

-

 

Loans payable – related parties

 

 

404,000

 

 

 

219,000

 

Total current liabilities

 

 

2,092,108

 

 

 

1,168,693

 

 

 

 

 

 

 

 

 

 

TOTAL LIABILITIES

 

 

2,092,108

 

 

 

1,168,693

 

 

 

 

 

 

 

 

 

 

Commitments and Contingencies

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Stockholders’ Equity (Deficit)

 

 

 

 

 

 

 

 

Series A Convertible Preferred Stock - $0.001 par value, 1,000,000 shares Authorized and 0 shares issued and outstanding

 

 

-

 

 

 

-

 

Common Stock - $0.001 par value, 300,000,000 shares Authorized, 228,877,509 and 228,667,229 shares issued at March 31, 2022 and December 31, 2021

 

 

228,877

 

 

 

228,667

 

Additional Paid-In Capital

 

 

71,109,164

 

 

 

71,017,881

 

Accumulated Deficit

 

 

(73,352,706 )

 

 

(72,388,442 )

Total Stockholders’ Equity (Deficit)

 

 

(2,014,665 )

 

 

(1,141,894 )

 

 

 

 

 

 

 

 

 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

 

$77,443

 

 

$26,799

 

 

See notes to unaudited condensed financial statements.

 

 
3

Table Of Contents

 

UNITED HEALTH PRODUCTS, INC.

Condensed Statements of Operations

(Unaudited)

 

 

 

For the Three Months Ended

March 31,

 

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

Revenues

 

$-

 

 

$59

 

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

 

-

 

 

 

25

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

-

 

 

 

34

 

 

 

 

 

 

 

 

 

 

Operating Costs and Expenses

 

 

 

 

 

 

 

 

Selling, general and administrative expenses

 

 

902,146

 

 

 

26,647,045

 

Research and development

 

 

52,355

 

 

 

58,180

 

Total Operating Expenses

 

 

954,501

 

 

 

26,705,225

 

 

 

 

 

 

 

 

 

 

Income/(Loss) from Operations

 

 

(954,501 )

 

 

(26,705,191 )

 

 

 

 

 

 

 

 

 

Other income (expense)

 

 

 

 

 

 

 

 

Interest expense

 

 

(80 )

 

 

(221,226 )

 Interest expense – related party

 

 

(8,808 )

 

 

(389,804 )

 Loss on settlement of debt

 

 

(875 )

 

 

(35,190 )

 Other income

 

 

-

 

 

 

304,273

 

 

 

 

 

 

 

 

 

 

Total other income (expense)

 

 

(9,763 )

 

 

(341,947 )

 

 

 

 

 

 

 

 

 

Net Income/(Loss)

 

$(964,264 )

 

$(27,047,138 )

 

 

 

 

 

 

 

 

 

Net Loss per common share:

 

 

 

 

 

 

 

 

Basic and diluted

 

$(0.00 )

 

$(0.12 )

 

 

 

 

 

 

 

 

 

Weighted average number of shares outstanding

 

 

228,726,869

 

 

 

222,059,641

 

 

See notes to unaudited condensed financial statements.

 

 
4

Table Of Contents

 

UNITED HEALTH PRODUCTS, INC

Condensed Statement of Stockholders’ Deficiency

Three Months Ended March 31, 2022 and March 31, 2021

(Unaudited)

 

 

 

 

 

 

 

  Additional

 

 

 

 

 

 

 

  Common Stock

 

 

  Paid-in

 

 

Accumulated

 

 

 

 

 

 

  Shares

 

 

  Amount

 

 

  Capital

 

 

Deficit

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31, 2020 (audited)

 

 

189,357,090

 

 

$189,357

 

 

$40,696,640

 

 

$(41,839,259 )

 

$(953,262 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Beneficial conversion feature

 

 

-

 

 

 

-

 

 

 

234,912

 

 

 

-

 

 

 

234,912

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock for services

 

 

100,000

 

 

 

100

 

 

 

110,900

 

 

 

-

 

 

 

111,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sale of common stock

 

 

125,000

 

 

 

125

 

 

 

99,875

 

 

 

-

 

 

 

100,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cancellation of common stock

 

 

(117,647 )

 

 

(117 )

 

 

117

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

33,930,000

 

 

 

33,930

 

 

 

26,136,491

 

 

 

-

 

 

 

26,170,421

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock issued to settle accrued liabilities – related party

 

 

152,835

 

 

 

153

 

 

 

161,811

 

 

 

-

 

 

 

161,964

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock issued to settle related party advances

 

 

25,000

 

 

 

25

 

 

 

26,725

 

 

 

-

 

 

 

26,750

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock issued for conversion of convertible notes payable and accrued interest

 

 

1,047,139

 

 

 

1,047

 

 

 

559,024

 

 

 

-

 

 

 

560,071

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock issued for conversion of convertible notes payable and accrued interest – related party

 

 

1,353,111

 

 

 

1,353

 

 

 

675,202

 

 

 

-

 

 

 

676,555

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(27,047,138 )

 

 

(27,047,138 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at March 31, 2021

 

 

225,972,528

 

 

$225,973

 

 

$68,701,697

 

 

$(68,886,397 )

 

$41,273

 

 

Balance at December 31, 2021 (audited)

 

 

228,667,229

 

 

$228,667

 

 

$71,017,881

 

 

$(72,388,442 )

 

$(1,141,894 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock for services

 

 

20,000

 

 

 

20

 

 

 

10,180

 

 

 

-

 

 

 

10,200

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sale of common stock

 

 

184,028

 

 

 

184

 

 

 

77,108

 

 

 

-

 

 

 

77,292

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock issued to settle accounts payable and accrued liabilities

 

 

6,252

 

 

 

6

 

 

 

3,995

 

 

 

-

 

 

 

4,001

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(964,264 )

 

 

(964,264 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at March 31, 2022

 

 

228,877,509

 

 

$228,877

 

 

$71,109,164

 

 

$(73,352,706 )

 

$(2,014,665 )

 

See notes to unaudited condensed financial statements.

 

 
5

Table Of Contents

 

UNITED HEALTH PRODUCTS, INC.

Condensed Statements of Cash Flows

(Unaudited)

 

 

 

For the Three Months

Ended March 31,

 

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

Cash Flows from Operating Activities:

 

 

 

 

 

 

Net (Loss)

 

$(964,264 )

 

$(27,047,138 )

Adjustments to Reconcile net (loss) to Net Cash Used In Operating Activities:

 

 

 

 

 

 

 

 

Stock for services and compensation

 

 

10,200

 

 

 

26,281,421

 

Amortization expense

 

 

1,012

 

 

 

-

 

Amortization of debt discount

 

 

-

 

 

 

604,521

 

Loss on settlement of debt

 

 

875

 

 

 

35,190

 

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

Inventory

 

 

-

 

 

 

25

 

Prepaid and other current assets

 

 

-

 

 

 

(5,000 )

Subscription Receivable

 

 

-

 

 

 

(50,000 )

Accounts payable and accrued expenses

 

 

191,052

 

 

 

(46,312 )

Accrued liabilities – related party

 

 

135,409

 

 

 

116,805

 

Accrued litigation settlement

 

 

430,000

 

 

 

-

 

Net Cash Used In Operating Activities

 

 

(195,716 )

 

 

(110,488 )

 

 

 

 

 

 

 

 

 

Cash Flows from Investing Activities:

 

 

 

 

 

 

 

 

Purchase of intangible assets

 

 

(40,500 )

 

 

-

 

Net Cash Used in Investing Activities

 

 

(40,500 )

 

 

-

 

 

 

 

 

 

 

 

 

 

Cash Flows from Financing Activities:

 

 

 

 

 

 

 

 

Proceeds from related party

 

 

185,000

 

 

 

20,000

 

Repayments on loan payable

 

 

(14,920 )

 

 

-

 

Proceeds from sale of common stock

 

 

77,292

 

 

 

100,000

 

Proceeds from convertible notes payable

 

 

-

 

 

 

115,000

 

Cash flow provided by financing activities

 

 

247,372

 

 

 

235,000

 

Increase in Cash and Cash Equivalents

 

 

11,156

 

 

 

124,512

 

Cash and Cash Equivalents – Beginning of period

 

 

21,799

 

 

 

46,076

 

 

 

 

 

 

 

 

 

 

CASH AND CASH EQUIVALENTS – END OF PERIOD

 

$32,955

 

 

$170,588

 

 

 

 

 

 

 

 

 

 

Supplemental cash flow information:

 

 

 

 

 

 

 

 

Cash paid for interest

 

$80

 

 

$-

 

Cash paid for income taxes

 

$-

 

 

$-

 

 

 

 

 

 

 

 

 

 

Non-cash Investing & Financing Activities:

 

 

 

 

 

 

 

 

Cancellation of common stock

 

$-

 

 

$117

 

Conversion of convertible notes payable and accrued interest – related party to convertible notes payable and accrued interest

 

$-

 

 

$176,502

 

Common stock issued for conversion of convertible notes payable and accrued interest – related party

 

$-

 

 

$676,555

 

Common stock issued for conversion of convertible notes payable and accrued interest

 

$-

 

 

$560,071

 

Conversion of accounts payable to convertible notes payable

 

$-

 

 

$90,000

 

Common stock issued to settle related party advances

 

$-

 

 

$26,750

 

Common stock issued to settle accrued liabilities – related party

 

$-

 

 

$161,964

 

Conversion of accrued liabilities – related party to convertible notes payable – related party

 

$-

 

 

$112,500

 

Common stock issued to settle accrued liabilities

 

$3,126

 

 

$-

 

Accrued litigation settlement paid with loan payable

 

$100,000

 

 

$-

 

Debt discount related to beneficial conversion feature

 

$-

 

 

$234,912

 

 

See notes to unaudited condensed financial statements.

 

 
6

Table Of Contents

 

UNITED HEALTH PRODUCTS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE QUARTERS ENDED MARCH 31, 2022 AND 2021

(Unaudited)

 

Note 1. Organization and Basis of Preparation

 

United Health Products, Inc. (the “Company”) develops, manufactures, and markets a patented hemostatic gauze for the healthcare and wound care sectors. Our gauze product, HemoStyp®, is a neutralized, oxidized, regenerated cellulose (“NORC”) derived from cotton and designed to absorb exudate/drainage from superficial wounds and help control bleeding. We are in the process of seeking regulatory approval to sell our Hemostyp product line into the U.S. Class III and European Union CE Mark surgical markets.

 

The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on April 1, 2022.

 

In the opinion of management, all adjustments, which are of a normal recurring nature, considered necessary for the fair presentation of financial statements for the interim period, have been included.

 

Note 2. Significant Accounting Policies

 

Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred recurring net losses, negative working capital and operations have not provided cash flows. Additionally, the Company does not currently have sufficient revenue producing operations to cover its operating expenses and meet its current obligations. In view of these matters, there is substantial doubt about the Company’s ability to continue as a going concern. The Company intends to finance its future development activities and its working capital needs largely from the sale of equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

On March 11, 2020, the World Health Organization declared the outbreak of a coronavirus (COVID-19) as a pandemic. As a result, economic uncertainties have arisen which have the potential to negatively impact the Company’s ability to raise funding and to pursue is business objectives. Other factors that carry financial implications for the Company could occur although the potential impacts are unknown at this time.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid debt investments purchased with a maturity of three months or less to be cash equivalents.

 

 
7

Table Of Contents

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reported period. Changes in the economic environment, financial markets, as well as in the healthcare industry, and any other parameters used in determining these estimates, could cause actual results to differ.

 

 Revenue Recognition

 

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the sale of its HemoStyp product by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.

 

The Company receives orders for its HemoStyp products directly from its customers. Revenues are recognized based on the agreed upon sales or transaction price with the customer when control of the promised goods are transferred to the customer. The transfer of goods to the customer and satisfaction of the Company’s performance obligation will occur either at the time when products are shipped or when the products arrive and are received by the customer. No discounts are currently offered by the Company. The Company does not provide an estimate for returns as there is no anticipation for any returns in the normal course of business.

 

Trade Accounts Receivable and Concentration Risk

 

We record accounts receivable at the invoiced amount and we do not charge interest. We review the accounts receivable by amounts due from customers that are past due, to identify specific customers with known disputes or collectability issues. In determining the amount of the reserve, we make judgments about the creditworthiness of significant customers based on ongoing credit evaluations. We will also maintain a sales allowance to reserve for potential credits issued to customers. We will determine the amount of the reserve based on historical credit issued.

 

There were no provisions for doubtful accounts recorded at March 31, 2022 and December 31, 2021. The Company recorded $0 and $0 in bad debt expense for the three month periods ended March 31, 2022 and 2021, respectively.

 

Stock Based Compensation

 

The Company accounts for share-based compensation under the provisions of ASC 718, Compensation-Stock Compensation. Under the fair value recognition provisions, stock-based compensation expense is measured at the fair value of the consideration received, or the fair value of the equity instruments issued, or liabilities incurred, whichever is more reliably measured. Share-based compensation for all stock-based awards to employees and directors is recognized as an expense over the requisite service period, which is generally the vesting period.

 

The Company accounts for stock compensation arrangements with non-employees in accordance with Accounting Standard Update (ASU) 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which requires that such equity instruments are recorded at the value on the grant date.

 

Per Share Information

 

Basic earnings per share are calculated using the weighted average number of common shares outstanding for the period presented. Diluted earnings per share is computed using the weighted-average number of common shares and, if dilutive, potential common shares outstanding during the period. The dilutive effect of potential common shares is not reflected in diluted earnings per share because the Company incurred net losses for the three months ended March 31, 2022 and 2021 and the effect of including these potential common shares in the net loss per share calculations would be anti-dilutive.

 

 
8

Table Of Contents

 

The total potential common shares as of March 31, 2022 included 28,190,000 of restricted stock units. The total potential common shares as of March 31, 2021 includes 27,400,000 of restricted stock units, and 35,294 shares for convertible loans payable - related party.

 

Patents

 

Patents are stated on the balance sheet at cost. Costs, such as filing fees with patent granting agencies and legal fees directly relating to those filings, incurred to file patent applications were capitalized when the Company believed that there was a high likelihood that the patent would be issued and there would be future economic benefit associated with the patent. These costs were amortized from the date of the patent application on a straight-line basis over the estimated useful life of 10 years. All costs associated with any abandoned patent applications are expensed.

 

Accumulated amortization as of March 31, 2022 and December 31, 2021 was $1,012 and $0, respectively. Amortization expense for the three months ended March 31, 2022 and 2021 was $1,012 and $0, respectively.

 

Future Amortization Expense

 

Year

 

Amount

 

2022 (remaining)

 

$3,038

 

2023

 

 

4,050

 

2024

 

 

4,050

 

2025

 

 

4,050

 

2026

 

 

4,050

 

Thereafter

 

 

20,250

 

 

 

$39,488

 

 

Impairment of Long-lived Assets

 

The Company applies the provisions of ASC 360, Property, Plant and Equipment, where applicable to all long-lived assets. ASC 360 addresses accounting and reporting for impairment and disposal of long-lived assets. The Company periodically evaluates the carrying value of long-lived assets to be held and used in accordance with ASC 360. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal.

 

When long-lived assets are sold or retired, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss is included in the results of operations. During the three months ended March 31, 2022 and 2021, the Company determined no impairment was required.

 

New Accounting Pronouncements

 

The Company considers all new pronouncements and management has determined that there have been no recently adopted or issued accounting standards that had or will have a material impact on its financial statements.

 

 
9

Table Of Contents

    

Note 3. Related Party Transactions

 

Loans payable - related parties

 

As of December 31, 2021, 21, Brian Thom, Chief Executive Officer had a loan payable balance of $175,000.

 

During the three months ended March 31, 2022, Mr. Thom loaned the Company $165,000 to pay for operating expenses. As of March 31, 2022, $340,000 is owed to Mr. Thom. The loans have an interest rate of 10% and have a maturity date of December 31, 2022.

 

As of December 31, 2021, Lou Schiliro, the former Chief Operating Officer, had a loan payable balance of $44,000.

 

During the three months ended March 31, 2022, Mr. Schiliro, loaned the Company $20,000 to pay for operating expenses. As of March 31, 2022, $64,000 is owed to Mr. Schiliro. The loans have an interest rate of 10% and have a maturity date of December 31, 2022.

 

Interest expense – related party on the above loans was $8,808 during the three months ended March 31, 2022. Accrued interest – related party as of March 31, 2022 and December 31, 2021 was $11,116 and $2,308, respectively.

 

Accrued liabilities – related parties

 

As of March 31, 2022 and December 31, 2021, $45,000 and $899 was owed to Mr. Thom for accrued compensation and reimbursable expenses, respectively.

 

As of March 31, 2022 and December 31, 2021, $45,000 and $0 was owed to Mr. Schiliro for accrued compensation, respectively.

 

As of March 31, 2022 and December 31, 2021, $37,500 and $0 was owed to Kristofer Heaton, the Principal Financial Officer, for accrued compensation, respectively.

 

Equity transactions

 

Per the vesting schedules of certain of the Company’s amended RSU Agreements, on January 1, 2021, 6,760,000 shares of common stock were issued to Mr. Douglas Beplate, former Chairman of the Board, 2,000,000 shares of common stock were issued to Mr. Schiliro and 100,000 shares of common stock were issued to Mr. Heaton.

 

 
10

Table Of Contents

 

On January 6, 2021, the Board of Directors approved the second amendment to the RSU Agreement between the Company and Mr. Beplate in conjunction with Mr. Beplate’s retirement from his day-to-day management role with the Company. The amendment accelerated the vesting and immediately settled his remaining RSUs by issuing 21,970,000 shares of common stock. Further, as a bonus in recognition of Mr. Beplate’s service to the Company and in recruitment of new executive management, the Company issued to Mr. Beplate an additional 2,000,000 shares of common stock. The Company recorded $26,127,300 of stock-based compensation expense during the three months ended March 31, 2021 related to the accelerated vesting of these RSU’s and issuance of common stock.

 

Note 4. Promissory Note Payable

 

During the three months ended March 31, 2022, the Company reached a settlement agreement related to Patterson’s counterclaim (see Note 6). The Company agreed to pay $120,000 which had previously been accrued as of December 31, 2021.

 

The Company paid $20,000 of the settlement and entered into a $100,000 promissory note with its legal counsel to fund the payment of the remaining balance. The Company paid $14,920 of principal and $80 in interest expense leaving a principal balance of $85,080 and accrued interest of $0 as of March 31, 2022. The note accrues interest at 1% and requires monthly payments of $9,136 until the balance is paid in full.

 

The promissory note is secured by 200,000 shares of restricted common stock which would have demand registration rights and the Company would file a registration statement within 45 days of the request.

 

Note 5. Issuances of Securities

 

Share issuances 2021

 

During the three months ended March 31, 2021, a total of 31,930,000 shares of common stock were issued to officers, directors and various consultants related to vesting of RSU’s with a total stock-based compensation cost of $23,990,421, 2,000,000 shares of common stock were issued to Mr. Beplate as a stock bonus with a stock-based compensation cost of $2,180,000, 125,000 shares of common stock were sold to an affiliated investor in a private placement for total cash proceeds of $100,000, 100,000 shares of common stock were issued for settlement of a business consulting agreement with a fair value of $111,000, 25,000 shares of commons stock were issued to settle $20,000 of related party advances, 152,835 shares of common stock were issued to settle $133,523 of accrued liabilities – related party, 1,047,139 shares of common stock were issued due to the conversion of convertible notes payable and accrued interest, 1,353,111 shares of common stock were issued due to the conversion of convertible notes payable and accrued interest – related party and 117,647 shares of common stock were cancelled.

 

Share issuances 2022

 

During the three months ended March 31, 2022, 184,028 shares of common stock were sold to non-affiliated investors in a private placement for total cash proceeds of $77,292, 6,252 shares of commons stock were issued to settle $3,126 of accrued liabilities resulting in a loss on settlement of debt of $875 and 20,000 shares of common stock with a fair value of $10,200 were issued for legal services.

 

Restricted stock units

 

As discussed in Note 3, during the year ended December 31, 2020 the Board of Directors approved amendments to its March 25, 2019 RSU Agreement for certain management and consultants to the Company.

 

The amendment resulted in 9,960,000 of the RSU’s vesting on January 1, 2021. The fair value of the 9,960,000 RSU’s. The compensation expense was being amortized on a straight-line basis from the date of the amendment through January 1, 2021 which is the vesting date. Stock-based compensation of $43,121 was recognized as expense during the three months ended March 31, 2021.

 

On January 6, 2021, the Board of Directors approved the second amendment to the Restricted Stock Unit Agreement between the Company and Mr. Beplate, former Chief Executive Officer and former Chairman of the Board, in conjunction with Mr. Beplate’s retirement from his day-to-day management role with the Company. The amendment accelerated the vesting and immediately settled his remaining RSUs by issuing 21,970,000 shares of common stock.

 

 
11

Table Of Contents

 

Per ASC 718-20-35, the change in vesting conditions resulted in a modification of the stock-based compensation awards. The modification is considered a Type III modification as described in ASC 718-20-55 and resulted in recording $23,947,300 of stock-based compensation expense which was the fair value of the shares on the date of the modification.

 

Activity related to our restricted stock units during the three months ended March 31, 2022 was as follows:

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

Average

 

 

 

 

 

 

Grant

 

 

 

Number of

 

 

Date Fair

 

 

 

Units

 

 

Value

 

Total awards outstanding at December 31, 2021

 

 

28,190,000

 

 

$0.96

 

Units granted

 

 

-

 

 

$-

 

Units Exercised/Released

 

 

-

 

 

$-

 

Units Cancelled/Forfeited

 

 

-

 

 

$-

 

Total awards outstanding at March 31, 2022

 

 

28,190,000

 

 

$0.96

 

 

Management is unable to predict if or when a Covered Transaction or Triggering Event under the RSU Agreements governing the restricted stock units will occur and as of March 31, 2022, there was $27,017,200 of unrecognized compensation cost related to unvested restricted stock unit awards.  

 

Note 6. Litigation

 

Philip Forman, who served as Chairman, a director, Chief Executive Officer and Chief Medical Advisor of the Company at various times between 2011 and October 2015, filed a lawsuit against the Company and our then-Chief Executive Officer, Douglas Beplate, in the United States District Court of the District of Nevada. The plaintiff has claimed, among other things: that the June 25, 2015 Amendment to his November 10, 2014 Employment Agreement with the Company, which terminated the Employment Agreement on October 1, 2015, is not enforceable due to lack of consideration; that a July 22, 2015 Stock Purchase Agreement pursuant to which the plaintiff sold Company shares issued to him under the Amendment to a third a party is unenforceable (despite the fact that all payment for the shares under the Stock Purchase Agreement was made); that the plaintiff’s 2014 Employment Agreement remains valid and that he is entitled to cash and stock compensation under that Employment Agreement (without giving regard to the Amendment); and that the Company and Mr. Beplate defrauded the plaintiff relating to the foregoing. The plaintiff is seeking declaratory judgment regarding the parties’ relative rights under the Employment Agreement, the Amendment and the Stock Purchase Agreement; money damages of no less than $2,795,000; and punitive damages of $8,280,000. The Company filed a motion to dismiss the plaintiff’s claims which was denied on March 19, 2020. On May 5, 2021, the plaintiff provided a deposition as instructed by the Court, subsequent to which the Company filed a motion for dismissal of this proceeding. On February 14, 2022, the Court issued an Order which declared the Amendment to be unenforceable and thus the terms of the original Employment Agreement to remain in effect. The Order also noted that the Company is not a party to the Stock Purchase Agreement, and the Employment Agreement does not constitute a prior agreement that could have been superseded by the Stock Purchase Agreement. The parties are currently engaged in settlement discussions.

 

In 2018 an action was commenced in the United States District Court Southern District of New York entitled JEC Consulting Associates, LLC. Liquidator of Lead Dog Capital LP against United Health Products t/k/a United EcoEnergy Corp and Douglas K. Beplate under Docket Number 18-cv-1139 (ER). The third-party action sought to remove a restrictive legend from a particular stock certificate for Three Million Fifty Thousand (3,050,000) shares and declare the shares to be free trading. The third-party plaintiff alleges that the Company and Mr. Beplate refused to have the restrictive legend on the stock certificate removed under Rule 144 and sought compensatory and punitive damages. The Federal court issued an order that the Securities Exchange Commission should review the claim before the District Court renders a final ruling. Discovery appears to be substantially complete and settlement discussions between the third-party plaintiff and the Company have been initiated. On April 22, 2022 the parties entered in a Settlement Agreement wherein the Company would agree to allow the removal of the restrictive legend as permitted under applicable securities laws and distribution of the shares to affiliates of the plaintiffs. Under the Settlement Agreement the Company will make no payments other than to pay expenses related to its own legal counsel.

 

 
12

Table Of Contents

 

Due to uncertainties inherent in litigation, we cannot predict the outcome of the above legal proceedings.

 

The Company has commenced the following legal proceedings:

 

On February 7, 2020, the Company filed the Original Petition for Fraud and Breach of Contract in the Texas District Court for the 215th Judicial District of Harris County against defendants Patterson Companies Inc., Patterson Management, L.P., Patterson Veterinary, Inc. and Patterson Logistics Services, Inc., and Animal Health International, Inc. On March 5, 2020, the defendants removed the case to U.S. District Court for Southern District of Texas. The defendants filed their answer in federal court on March 12, 2020. The original August 25, 2020 pretrial deadlines were extended. On January 18, 2022, the Company’s claims were dismissed, with prejudice, by the court. On February 9, 2022, the Company and Patterson reached an agreement on settlement of Patterson’s counterclaim. The Company agreed to pay $120,000 which was accrued as of December 31, 2021. The $120,000 settlement payment was paid in full in February 2022.

 

In August 2020, United Health Products filed suit against its former auditors, Haynie & Company, in Utah State Court, asserting claims related to professional negligence and breach of fiduciary duty. Haynie & Company has denied the allegations. Discovery is largely complete and the parties have each submitted a report by their respective expert witness to the Court.

 

Note 7. Other Income

 

The Company received payment of $304,273 from Maxim Group LLC, as full and final settlement of its previously disclosed arbitration between the Company and Maxim that was settled in December 2019. The $304,273 was recorded as other income in the Statement of Operations during the three months ended March 31, 2021. 

 

Note 8. Subsequent Events

 

The Company has evaluated events from March 31, 2022, through the date whereupon the financial statements were issued and has determined that there are no material events that need to be disclosed except as follows:

 

In connection with the Securities and Exchange Commission’s investigation against the Company, Douglas Beplate, the former Chief Executive Officer and Chairman and a former director of the Company, and Louis Schiliro, the former Chief Operating Officer and a former director of the Company, concerning possible violations of certain provisions of the Securities Act of 1933 and the Securities Exchange Act of 1934, the Commission’s Enforcement Division has presented proposed settlement terms which the Enforcement Division has indicated it would recommend to the Commission to resolve the matter as to the Company, if acceptable to the Company. The investigation was previously reported by the Company in its prior periodic reports including its Annual Report for the year ended December 31, 2021 under Item 1A “Risk Factors”.

 

 
13

Table Of Contents

 

The proposed resolution terms of the investigation presented by the Commission would include a consent judgment against the Company on the following terms, among others, without the Company admitting or denying the Commission’s allegations:

 

 

·

The Company being permanently enjoined from violating: Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 under the Exchange Act; Section 17(a) of the Securities Act of 1933; Section 13(a) of the Exchange Act and Rules 12b-20, 13a-1 and 13a-13 under the Exchange Act; Section 13(b)(2)(A) of the Exchange Act; and Section 13(b)(2)(B) of the Exchange Act.

 

 

 

 

·

The Company being required to pay a civil penalty of $450,000, payable in four installments as follows: $50,000 upon the entry of the judgment; $100,000 within 90 days of the entry of the judgment; $150,000 within 180 days of the entry of the judgment; and $150,000 within 270 days of the entry of the judgment, plus statutory interest on payments made after 30 days of the entry of the judgment pursuant to U.S.C. Section 1961.

  

Additionally, the Company’s consent would include the Company’s agreement not to take any action or make any public statement denying any allegations in the Commission’s complaint or creating the impression that the complaint is without factual basis; and not to make any public statement to the effect that the Company does not admit the allegations in the complaint without also stating that the Company does not deny the allegations.

 

The $450,000 civil penalty has been accrued as of March 31, 2022.

 

The Company received a total of $50,000 in advances from its Chief Executive Officer.

 

The Company issued a total of 1,250,000 shares of common stock to officers and various consultants for accrued compensation and services provided in lieu of cash salary payments due under their respective consulting agreements.

 

 
14

Table Of Contents

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

You should read the following discussion and analysis of our financial condition and results of operations together with our condensed financial statements and related notes appearing elsewhere in this quarterly report on Form 10-Q. This discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. The actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, but not limited to, those set forth under ‘Risk Factors’ in our annual report on Form 10-K for the fiscal year ended December 31, 2021, filed with SEC on April 1, 2022.

 

Company Overview

 

UHP develops, manufactures, and markets a patented hemostatic gauze for the healthcare and wound care sectors. Our gauze product, HemoStyp®, is a neutralized, oxidized, regenerated cellulose (“NORC”) derived from cotton and designed to absorb exudate/drainage from superficial wounds and help control bleeding. We are in the process of seeking regulatory approval to sell our Hemostyp product line into the U.S. Class III and European CE Mark surgical markets.

 

Our HemoStyp Gauze Products

 

HemoStyp hemostatic gauze is a collagen-like natural substance created from chemically treated cellulose derived from cotton. It is an effective hemostatic agent registered with the FDA for superficial use under a 510k approval obtained in 2012 to help control bleeding from open wounds and body cavities. The HemoStyp hemostatic material contains no chemical additives, thrombin, collagen or animal-derived products, and is hypoallergenic. When the product comes in contact with blood it expands slightly and quickly converts to a translucent gel that subsequently breaks down into glucose and salts. Because of its benign impact on body tissue and the fact that it degrades to non-toxic end products, HemoStyp does not impede the healing of body tissue as do certain competing hemostatic products. Laboratory testing has shown HemoStyp to be 100% absorbable in the human body within 24 hours, compared to days or weeks with competing organic regenerated cellulose products. A human trial conducted in 2019 and 2020 demonstrated the effectiveness of HemoStyp in vascular, thoracic and abdominal surgical procedures.

 

 
15

Table Of Contents

 

HemoStyp hemostatic gauze is a flexible, silk-like material that is applied by placing the gauze onto the bleeding tissue. The supple material can be easily folded and manipulated as needed to fit the size of the wound or incision. In surface bleeding and surgical situations, the product quickly converts to a translucent gel that allows the physician or surgeon to monitor the coagulation process. The gel maintains a neutral pH level which avoids damaging the surrounding tissue. In superficial bleeding situations, HemoStyp can be bonded to an adhesive plastic bandage or integrated into a traditional gauze component to address a broad range of needs, including traumatic bleeding injuries and prolonged bleeding following hemodialysis.

 

 Potential Target Markets

 

Our HemoStyp material is currently cut to several sizes and configuration and marketed as HemoStyp Gauze. While we have paused our commercial activities to focus on our Class III PMA application, our potential customer base includes, without limitation, the following:

 

 

·

Hospitals and Surgery Centers for all Internal Surgical usage (in the event we obtain FDA Class III approval)

 

·

Hospitals, Clinics and Physicians for external trauma

 

·

EMS, Fire Departments and other First Responders

 

·

Military Medical Care Providers

 

·

Hemodialysis centers

 

·

Nursing Homes and Assisted Living Facilities

 

·

Dental and Oral & Maxillofacial Surgery Offices

 

·

Veterinary hospitals

 

 Primary Strategy

 

Our HemoStyp technology received an FDA 510k approval in 2012 for use in external or superficial bleeding situations and we believe there is an opportunity for HemoStyp products to address unmet needs in several medical applications that represent attractive commercial opportunities. However, the Class III surgical markets, both domestic and international, represent the most attractive market for our products due to the smaller number of competitors offering Class III approved hemostatic agents and the resulting premium pricing for products that can meet the demanding requirements of the human surgical environment. Our extensive laboratory testing and our completed human trial indicate that the HemoStyp technology can successfully compete against established Class III market participants and allow us to gain a significant market share. There can be no assurance that an FDA PMA will be granted.

 

In 2018, we made the decision to focus our efforts and resources on accessing these Class III markets to maximize the value potential of our HemoStyp. The Class III PMA process required a substantial investment of time and resources so we made the strategic determination to pause our sales and marketing to non-Class III markets in order to devote our full attention to the FDA process. In the fourth quarter of 2021, with our PMA application largely complete and under review by the FDA, we re-engaged with certain consumers and distributors of 510-k hemostatic products with the objective of developing a revenue channel in this market going forward. Our primary market focus for this initiative includes the first aid, hemodialysis and emergency medicine sectors.

 

In anticipation of receiving a Class III PMA (which cannot be assured), we are evaluating paths to rapidly grow our revenue and profits in all potential market segments, with the objective of maximizing shareholder value. Options under consideration include (i) a sale or merger of the Company with an industry leader in the wound care and surgical device sectors, which may include a pre-sale collaboration on commercialization and distribution, (ii) one or more commercial partnerships with established market participants, without any specific, associated sale or merger transaction, and (iii) a capital raising program to establish and grow our own marketing and distribution capabilities and drive revenue and profits organically.

 

 
16

Table Of Contents

 

The Company has been contacted by several medical technology companies that are active in the surgical equipment and hemostatic products sectors, and who have expressed an interest in the Company’s products and business strategy. In response to these inbound contacts, we continue to engage in discussions to evaluate the potential commercial partnerships in anticipation of an FDA decision on our Class III PMA application. There can be no assurances that any specific transaction will occur as a result of these discussions. No assurances can be given that the Company will identify any commercialization candidate(s) or complete a transaction.

 

Manufacturing and Packaging of our Products

 

The Company’s NORC products are manufactured largely in the United States to our specifications and using our equipment through a contract manufacturing arrangement with an FDA certified contract manufacturer that maintains stringent quality control protocols to assure the uniformity and quality of all of our gauze products. Information on our equipment, the manufacturing process and our manufacturer’s facility has been submitted as part of our PMA submission, which includes the FDA inspection records of the facility. Certain of our adhesive bandage formats designed for the 510k market are manufactured by a separate contractor based in China.

 

Patents and Trademarks

 

Our NORC technology is protected through patents filed with the U.S. Patent and Trademark Office, which protection currently runs through 2029. In 2020 and 2021, we filed additional U.S. and International patents that protect the use of our NORC technology in a gel or hydrocolloid formulation.

 

On January 21, 2021, the U.S. Patent Office provided notification of publication of the Company’s patent application for the method of forming and using a hemostatic hydrocolloid. This publication does not imply any assurance of the receipt of the patent but establishes an obligation of any party that seeks to use the applicable method to pay royalties for the right to do so. The patent application for this process remains pending as of the date of this filing.

 

On February 11, 2021, the Company was notified that its application to establish global patent protection for the process of creating and deploying a hydrocolloid (or gel) format of its HemoStyp technology was accepted for publication under the procedures of the Patent Cooperation Treaty (“PCT”), an international patent law treaty which provides a unified procedure for filing a patent application in most foreign countries. We previously filed provisional patent applications for our HemoStyp hydrocolloid process in 2020. In January 2022 the Company initiated steps to register its hydrocolloid patent in the European common market and in additional foreign countries where we intend to commercialize any future HemoStypo gel formats. We can give no assurance that foreign registration of our patents will be granted in any of these jurisdictions.

 

The Company has registered trademarks for the following product formats:

 

 

·

Boo Boo Strips

 

·

The Ultimate Bandage

 

·

Hemostrips

 

·

Nik Fix

 

 
17

Table Of Contents

 

Results of Operations for the three months ending March 31, 2022 and 2021

 

The following table sets forth a summary of certain key financial information for the three months ended March 31, 2022 and 2021:

 

 

 

For the Three Months

Ended March 31,

 

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

Revenue

 

$-

 

 

$59

 

 

 

 

 

 

 

 

 

 

Gross profit

 

$-

 

 

$34

 

 

 

 

 

 

 

 

 

 

Operating (expenses)

 

$(954,501 )

 

$(26,705,225 )

 

 

 

 

 

 

 

 

 

Operating (loss)

 

$(954,501 )

 

$(26,705,191 )

 

 

 

 

 

 

 

 

 

Other income (expense)

 

$(9,763 )

 

$(341,947 )

 

 

 

 

 

 

 

 

 

Net (loss)

 

$(964,264 )

 

$(27,047,138 )

 

 

 

 

 

 

 

 

 

Basic and diluted

 

$(0.00 )

 

$(0.12 )

 

Three Months ended March 31, 2022 versus Three Months ended March 31, 2021

 

During the first quarter of 2022 and 2021, the Company had $0 and $59 of revenues, respectively. The minimal revenues are due to the continued focus of the Company’s capital and resources towards obtaining a Class III PMA.

 

Total operating expenses for the first quarter of 2022 and 2021 were $954,501 and $26,705,225, respectively.

 

The decrease in operating expenses is due primarily to a decrease in stock for services and compensation expense of $26,271,221. The Company recorded a total $10,200 of stock for services and compensation during the three months ended March 31, 2022 compared to $26,281,421 during the three months ended March 31, 2021.

 

The decrease in stock for services compensation is due to the Company issuing 20,000 shares of common stock for services with a fair value of $10,200 during the three months ended March 31, 2022. Stock for services and compensation during the three months ended March 31, 2021 was primarily due to the vesting and amortization of RSUs. During the three months ended March 31, 2021, the Company amended the RSU agreement with its former Chief Executive Officer and Chairman. The amendment resulted in the vesting of 21,970,000 RSUs along with the issuance of an additional 2,000,000 shares of restricted stock as a bonus. The change in vesting and issuance of the bonus shares of common stock resulted in the immediate recognition of $26,127,300 in stock-based compensation expense. The Company also recognized $43,121 of stock-based compensation due to the amortization of the RSUs that vested on January 1, 2021 and issued 100,000 shares of common stock for settlement of a consulting agreement valued at $111,000.

 

Other income (expense) for the first quarter of 2022 and 2021 was $(9,763) and $(341,947), respectively. The decrease in other expense was due to a decrease in total interest expense of $602,142, a decrease in loss on settlement of debt $34,415 and a decrease in other income of $304,273. The decrease in interest expense is primarily due to the Company only having total interest expense of $8,880 during the first quarter of 2022 compared to the Company having total interest expense of $611,030 primarily due to recording amortization of beneficial conversion features on convertible notes payable and convertible notes payable – related party to interest expense during the first quarter 2021 totaling $604,521. The decrease in the loss on debt settlement is due to the Company issuing common stock with a fair value of $4,001 for the settlement of $3,126 of accrued liabilities during the first quarter of 2022 compared to the Company issuing common stock with a fair value of $188,713 for the settlement of $153,523 of various debts and accrued liabilities – related party. The Company did not have Other income during 2022 compared to the Company receiving $304,273 as full and final payment for settlement of its December 2019 arbitration with Maxim during the first quarter of 2021.

 

 
18

Table Of Contents

 

Our net loss for the quarter ended March 31, 2022 was $964,264 as compared to net loss of $27,047,138 for the comparable period of the prior year. The decrease in the net loss is due to the Company having a decrease in operating expenses of $25,750,724 and a decrease in other expenses of $332,184, as explained above.

 

Financial Condition, Liquidity and Capital Resources

 

As of March 31, 2022, the Company had a negative working capital of $2,054,153. The Company has not yet attained a level of operations which will allow it to meet its current overhead expense obligations. If we are not successful in our commercialization strategy, we cannot assure that we will be able to fund a standalone marketing and sale strategy, and if we do, we are unable to assure we will attain profitable operations within the next year or at all. The report of our independent registered public accounting firm on our 2021 financial statements includes an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern. While the Company has funded its operations with private placements, and secured loans from related parties, there can be no assurance that adequate financing will continue to be available to the Company and, if available, on terms that are favorable to the Company. Our ability to continue as a going concern is also dependent on many events outside of our direct control, including, among other things, our ability to achieve our business goals and objectives.

 

Cash Flows

 

The Company’s cash on hand at March 31, 2022 and December 31, 2021 was $32,955 and $21,799, respectively.

 

The following table summarizes selected items from our statements of cash flows for the three months ended March 31, 2022 and 2021:

 

 

 

For the Three Months

Ended March 31,

 

 

 

2022

 

 

2021

 

Net cash used in operating activities

 

$(195,716 )

 

$(110,488 )

Net cash used in investing activities

 

 

(40,500 )

 

 

-

 

Net cash provided by financing activities

 

 

247,372

 

 

 

235,000

 

 

 

 

 

 

 

 

 

 

Net increase in cash and cash equivalents

 

$11,156

 

 

$124,512

 

 

Net Cash Provided by (Used in) Operating Activities

 

Net cash used in operating activities for the three months ended March 31, 2022 was $195,716. The Company had net loss of $964,264 offset by stock for services and compensation of $10,200, amortization expense of $1,012, a loss on debt settlement of $875, an increase in accounts payable and accrued expenses of $191,052, an increase in accrued liabilities - related party of $135,409 and an increase in accrued litigation settlement of $430,000.

 

Net cash used in operating activities for the three months ended March 31, 2021 was $110,488. The Company had net loss of $27,047,138 offset by stock-based compensation of $26,281,421, amortization of debt discount of $604,521 and a loss on settlement of debt of $35,190. The Company also had a decrease in inventory of $25, change in accounts payable and accrued expenses of $(46,312) and a change in accounts payable and accrued expenses related party of $116,805. The Company also had an increase in prepaid and other current assets of $5,000 and an increase in subscription receivable of $50,000.

 

 
19

Table Of Contents

 

Net Cash Used by Investing Activities

 

The Company paid $40,500 related to the patent application fees during the three months ended March 31, 2022.

 

The Company did not have any investing activities during the three months ended March 31, 2021.

 

Net Cash Provided by (Used in) Financing Activities

 

Net cash provided by financing activities for the three months ended March 31, 2022 was $247,372. This was due to the result of the Company receiving $77,292 in proceeds from the sale of stock and receiving $185,000 from related party loans offset by making payments of $(14,920) on loan payable.

 

Net cash provided by financing activities for the three months ended March 31, 2021 was $235,000. This was to the result of the Company receiving $20,000 in proceeds from a related party loan, $100,000 in proceeds from the sale of stock and receiving $115,000 in proceeds from the issuance of convertible notes.

 

Off-Balance Sheet Arrangements

 

As of March 31, 2022, we have no off-balance sheet arrangements.

 

Critical Accounting Policies

 

The preparation of financial statements and related disclosures in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the periods reported. Actual results could materially differ from those estimates. We have identified the following items as critical accounting policies.

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the sale of its HemoStyp product by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.

 

The Company receives orders for its HemoStyp products directly from its customers. Revenues are recognized based on the agreed upon sales or transaction price with the customer when control of the promised goods are transferred to the customer. The transfer of goods to the customer and satisfaction of the Company’s performance obligation will occur either at the time when products are shipped or when the products arrive and are received by the customer. No discounts were offered by the Company. The Company does not provide an estimate for returns as there is no anticipation for any returns in the normal course of business.

 

 
20

Table Of Contents

 

Stock Based Compensation

 

The Company accounts for share-based compensation under the provisions of ASC 718, Compensation-Stock Compensation. Under the fair value recognition provisions, stock-based compensation expense is measured at the fair value of the consideration received, or the fair value of the equity instruments issued, or liabilities incurred, whichever is more reliably measured. Share-based compensation for all stock-based awards to employees and directors is recognized as an expense over the requisite service period, which is generally the vesting period.

 

The Company accounts for stock compensation arrangements with non-employees in accordance with Accounting Standard Update (ASU) 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which requires that such equity instruments are recorded at the value on the grant date.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

 

Not applicable 

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

The Company is in the process of implementing disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the ‘‘Exchange Act’’), that are designed to ensure that information required to be disclosed in the Company’s Exchange Act reports are recorded, processed, summarized, and reported within the time periods specified in rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to our Chief Executive Officer and Principal Financial Officer to allow timely decisions regarding required disclosure.

 

As of March 31, 2022, the Chief Executive Officer and the Principal Financial Officer carried out an assessment of the effectiveness of the design and operation of our disclosure controls and procedures and concluded that the Company’s disclosure controls and procedures were not effective.

 

Changes in Internal Control over Financial Reporting

 

During the three months ended March 31, 2022, there were no changes in our system of internal controls over financial reporting.

 

 
21

Table Of Contents

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings

 

See “Note 6” in the Notes to Condensed Financial Statements.

 

Item 1A. Risk Factors

 

Management does not believe there have been any material changes to the risk factors listed in Part I, “Item 1A, Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2021. These risk factors should be carefully considered with the information provided elsewhere in this report, which could materially adversely affect our business, financial condition or results of operations.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

The following summarizes all sales of our unregistered securities from January 1, 2022 through March 31, 2022. The securities in the below-referenced transactions were (i) issued without registration and (ii) were subject to restrictions under the Securities Act and the securities laws of certain states, in reliance on the private offering exemptions contained in Sections 4(a)(2), 4(a)(6) and/or 3(b) of the Securities Act and on Regulation D promulgated under the Securities Act, and in reliance on similar exemptions under applicable state laws as transactions not involving a public offering. No placement or underwriting fees were paid in connection with these transactions. All cash proceeds from the sale of securities were used for working capital purposes.

 

Date of Sale

 

Title of Security

 

Number Sold

 

Consideration Received

January 2022

 

Common Stock

 

6,252

 

$3,126 of accrued liabilities

 

February 2022

 

Common Stock

 

184,028

 

$77,292 in cash at $0.42 per share

 

February 2022

 

Common Stock

 

20,000

 

$10,200 in services provided

 

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

Not applicable.

 

 
22

Table Of Contents

 

Item 6. Exhibits

 

The following exhibits are filed with this report, or incorporated by reference as noted:

 

3(i)

 

Articles of Incorporation of the Company dated February 28, 1997. (1)

 

 

 

3(ii)

 

Amendment to Articles of Incorporation. (1)

 

 

 

3(iii)

 

By-laws of the Company. (2)

 

 

 

3(iv)

 

August 2015 Amendment to Articles of Incorporation. (3)

 

 

 

10.1

 

Services Agreement with Louis Schiliro (4)

 

 

 

10.2

 

Restricted Stock Unit Agreement – Louis Schiliro (5)

 

 

 

10.3

 

Restricted Stock Unit Agreement – Doug Beplate (5)

 

 

 

10.4

 

Services Agreement with Brian Thom (6)

 

 

 

10.5

 

Restricted Stock Unit Agreement - Brian Thom (6)

 

 

 

10.6

 

Services Agreement with Kristofer Heaton (7)

 

 

 

10.7

 

Restricted Stock Unit Agreement - Kristofer Heaton (7)

 

 

 

21

 

Subsidiaries of the Registrant – none

 

 

 

31.1

 

Certification of Principal Executive Officer*

 

 

 

31.2

 

Certification of Principal Financial Officer*

 

 

 

32.1

 

Section 1350 Certificate by Principal Executive Officer*

 

 

 

32.2

 

Section 1350 Certificate by Principal Financial Officer*

 

 

 

99.1

 

2019 Employee Benefit and Consulting Services Compensation Plan (8)

 

 
23

Table Of Contents

 

101.INS

 

Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).

 

 

 

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document.

 

 

 

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

 

 

 

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document.

 

 

 

101.LAB

 

Inline XBRL Taxonomy Extension Labels Linkbase Document.

 

 

 

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

 

 

 

104

 

Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

___________

* Filed herewith.

 

(1)

Incorporated by reference to the Company’s Form 10-Q for the quarter ended September 30, 2014.

 

 

(2)

Incorporated by reference to the Company’s Form 10-K for the year ended December 31, 2005.

 

 

(3)

Incorporated by reference to Form 8-K dated August 7, 2015 – date of earliest event filed on August 10, 2015.

 

 

(4)

Incorporated by reference to the Company’s Form 10-Q for the quarter ended June 30, 2018.

 

 

(5)

Incorporated by reference to the Company’s Form 10-K for the year ended December 31, 2018.

 

 

(6)

Incorporated by reference to the Form 8-K dated December 2, 2020

 

 

(7)

Incorporated by reference to the Form 8-K dated January 11, 2021

 

 

(8)

Incorporated by reference to Form S-8 dated November 1, 2019

 

 
24

Table Of Contents

 

SIGNATURES

 

Pursuant to the requirements Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

UNITED HEALTH PRODUCTS, INC.

Dated: May 13, 2022

By:

/s/ Brian Thom

Brian Thom

Principal Executive Officer

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:

 

Signatures

Title

Date

By:

/s/ Brian Thom

 

May 13, 2022

Brian Thom

Chief Executive Officer, Principal Executive Officer and Director

 

 

 

 

 

 

By:

/s/ Kristofer Heaton

Vice President, Finance and Principal Financial Officer

May 13, 2022

Kristofer Heaton

 

 

 

 

 

 

 

By:

/s/ Robert Denser

Director

May 13, 2022

Robert Denser

 

 
25

 

EX-31.1 2 ueec_ex311.htm CERTIFICATION ueec_ex311.htm

 

EXHIBIT 31.1

 

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

 

I, Brian Thom certifies that:

 

1. 

I have reviewed this quarterly report on Form 10-Q of United Health Products, Inc.;

 

2

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. 

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. 

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) 

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) 

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) 

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) 

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a) 

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) 

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 13, 2022

By:

/s/ Brian Thom

 

 

Brian Thom

 

 

Principal Executive Officer

 

 

 

EX-31.2 3 ueec_ex312.htm CERTIFICATION ueec_ex312.htm

EXHIBIT 31.2

 

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

 

I, Kristofer Heaton certifies that:

 

1. 

I have reviewed this quarterly report on Form 10-Q of United Health Products, Inc.;

 

2

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. 

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. 

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) 

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) 

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) 

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) 

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a) 

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) 

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 13, 2022

By

/s/ Kristofer Heaton

 

Kristofer Heaton

 

Principal Financial Officer

 

EX-32.1 4 ueec_ex321.htm CERTIFICATION ueec_ex321.htm

 

EXHIBIT 32.1

 

CERTIFICATION

 

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350), Brian Thom, Principal Executive Officer of United Health Products, Inc. (the “Company”) of the Company, hereby certifies that, to the best of his knowledge:

 

 

1.

The Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, to which this Certification is attached as Exhibit 32.1 (the “Quarterly Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and

 

 

 

 

2.

The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

In witness whereof, the undersigned have set their hands hereto as of the May 13, 2022.

 

By:

/s/ Brian Thom

 

 

 

Brian Thom

 

 

 

Principal Executive Officer

 

 

EX-32.2 5 ueec_ex322.htm CERTIFICATION ueec_ex322.htm

EXHIBIT 32.2

 

CERTIFICATION

 

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350), Kristofer Heaton, Principal Financial Officer of United Health Products, Inc. (the “Company”) of the Company, hereby certifies that, to the best of his knowledge:

 

 

1.

The Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, to which this Certification is attached as Exhibit 32.2 (the “Quarterly Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and

 

 

 

 

2.

The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

In witness whereof, the undersigned have set their hands hereto as of the May 13, 2022.

 

By:

/s/ Kristofer Heaton

 

 

 

Kristofer Heaton

 

 

 

Principal Financial Officer

 

 

EX-101.SCH 6 ueec-20220331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - Condensed Statement of Stockholders Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000007 - Disclosure - Organization and Basis of Preparation link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - Promissory Note Payable link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - Issuances of Securities link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - Litigation link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - Other Income link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - Issuances of Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - Promissory Note Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - Issuances of Securities (Details) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - Issuances of Securities (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - Litigation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - Other Income (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 7 ueec-20220331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Document Quarterly Report Document Transition Report Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Interactive Data Current Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Entity Address Address Line 1 Condensed Balance Sheets ASSETS Current Assets Cash and Cash Equivalents Prepaid and other current assets Total current assets [Assets, Current] Patents, net TOTAL ASSETS [Assets] Current Liabilities Accounts payable and accrued expenses Accrued liabilities - related parties Accrued litigation settlement Promissory note payable Loans payable - related parties Total current liabilities [Liabilities, Current] TOTAL LIABILITIES [Liabilities] Commitments and Contingencies Stockholders' Equity (Deficit) Series A Convertible Preferred Stock - $.001 par value, 1,000,000 shares Authorized and 0 shares issued and outstanding Common Stock - $.001 par value, 300,000,000 shares Authorized, 228,877,509 and 228,667,229 shares issued at March 31, 2022 and December 31, 2021 Additional Paid-In Capital [Additional Paid in Capital] Accumulated Deficit [Retained Earnings (Accumulated Deficit)] Total Stockholders' Equity (Deficit) [Stockholders' Equity Attributable to Parent] TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) [Liabilities and Equity] Statement [Table] Statement [Line Items] Statement Class Of Stock Axis Series A Convertible Preferred Stock [Member] Common stock, shares par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Preferred Stock, shares par value Preferred Stock, shares authorized Preferred Stock, shares issued Preferred Stock, shares outstanding Condensed Statements of Operations (Unaudited) Revenues Cost of goods sold Gross profit [Gross Profit] Operating Costs and Expenses Selling, general and administrative expenses Research and development Total Operating Expenses [Operating Expenses] Income/(Loss) from Operations [Operating Income (Loss)] Other income (expense) Interest expense [Interest Expense] Interest expense - related party [Interest Expense, Related Party] Loss on settlement of debt Other income Total other income (expense) [Other Nonoperating Income (Expense)] Net Income/(Loss) [Net Income (Loss) Attributable to Parent] Net Loss per common share: Basic and diluted Weighted average number of shares outstanding Condensed Statement of Stockholders Equity (Unaudited) Statement Equity Components [Axis] Common Stock [Member] Additional Paid-In Capital Additional Paid-in Capital [Member] Accumulated Deficit Retained Earnings [Member] Balance, shares [Shares, Issued] Balance, amount Beneficial conversion feature Issuance of common stock for services, shares Issuance of common stock for services, amount Sale of common stock, shares Sale of common stock, amount Cancellation of common stock, shares Cancellation of common stock, amount Stock-based compensation, shares Stock-based compensation, amount Common stock issued to settle accrued liabilities - related party, shares Common stock issued to settle accrued liabilities - related party, amount Common stock issued to settle related party advances, shares Common stock issued to settle related party advances, amount Common stock issued for conversion of convertible notes payable and accrued interest, shares Common stock issued for conversion of convertible notes payable and accrued interest, amount Common stock issued for conversion of convertible notes payable and accrued interest - related party, shares Common stock issued for conversion of convertible notes payable and accrued interest - related party, amount Net Loss Common stock issued to settle accounts payable and accrued liabilities, shares Common stock issued to settle accounts payable and accrued liabilities, amount Balance, shares Balance, amount Condensed Statements of Cash Flows (Unaudited) Cash Flows from Operating Activities: Net (Loss) [Net Income (Loss), Including Portion Attributable to Noncontrolling Interest] Adjustments to Reconcile net (loss) to Net Cash Used In Operating Activities: Stock for services and compensation Amortization expense Amortization of debt discount Loss on settlement of debt Changes in assets and liabilities: Inventory [Increase (Decrease) in Inventories] Prepaid and other current assets [Increase (Decrease) in Other Current Assets] Subscription Receivable [Subscription Receivable] Accounts payable and accrued expenses [Increase (Decrease) in Accounts Payable and Accrued Liabilities] Accrued liabilities - related party Accrued litigation settlement [Accrued litigation settlement] Net Cash Used In Operating Activities [Net Cash Provided by (Used in) Operating Activities] Cash Flows from Investing Activities: Purchase of intangible assets [Payments to Acquire Short-term Investments] Net Cash Used in Investing Activities [Net Cash Provided by (Used in) Investing Activities] Cash Flows from Financing Activities: Proceeds from related party Repayments on loan payable [Repayments of Notes Payable] Proceeds from sale of common stock Proceeds from convertible notes payable [Proceeds from convertible notes payable] Cash flow provided by financing activities [Net Cash Provided by (Used in) Financing Activities] Increase in Cash and Cash Equivalents [Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect] Cash and Cash Equivalents - Beginning of period [Cash and Cash Equivalents, at Carrying Value] CASH AND CASH EQUIVALENTS - END OF PERIOD Supplemental cash flow information: Cash paid for interest Cash paid for income taxes Non-cash Investing & Financing Activities: Cancellation of common stock Conversion of convertible notes payable and accrued interest - related party to convertible notes payable and accrued interest Common stock issued for conversion of convertible notes payable and accrued interest - related party Common stock issued for conversion of convertible notes payable and accrued interest Conversion of accounts payable to convertible notes payable Common stock issued to settle related party advances Common stock issued to settle accrued liabilities - related party Conversion of accrued liabilities - related party to convertible notes payable - related party Common stock issued to settle accrued liabilities Accrued litigation settlement paid with loan payable Debt discount related to beneficial conversion feature Organization and Basis of Preparation Organization and Basis of Preparation Business Description and Basis of Presentation [Text Block] Significant Accounting Policies Significant Accounting Policies Significant Accounting Policies [Text Block] Related Party Transactions Related Party Transactions Related Party Transactions Disclosure [Text Block] Promissory Note Payable [Promissory Note Payable] Issuances of Securities Issuances of Securities [Issuances of Securities] Litigation Litigation Legal Matters and Contingencies [Text Block] Other income Other Income and Other Expense Disclosure [Text Block] Subsequent Event Subsequent Events Going Concern Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Use of Estimates Revenue Recognition Trade Accounts Receivable and Concentration Risk Stock Based Compensation Per Share Information Patents Impairment of Long-lived Assets New Accounting Pronouncements Schedule of Future Amortization Expense Schedule of Restricted stock units 2022 (remaining) 2023 2024 2025 2026 Thereafter Future Amortization Expense Restricted Stock Units [Member] Accumulated amortization Bad debt expense Amortization expense [Exploration Expense] Description of patent Convertible loans Payable shares, related party Potential antidilutive shares Title Of Individual Axis Related Party Transaction Axis Related Party Transactions By Related Party Axis Louis Schiliro [Member] Brian Thom [Member] Mr. Beplate [Member] Kristofer Heaton [Member] Douglas Beplate [Member] Loan from related party Restricted stock units granted Amount owed Interest Rate Maturity Date Reimbursable expenses Accrued compensation Operating expenses Accrued interest Remaining balance Convertible loans payable - related parties Stock based compensation Common stock share issued Converted loans payable and accrued liabilities Additional RSU's issued Payment of compensation RSU granted to officers, directors and consultants Promissory Note Payable (Details Narrative) Legal Counsel [Member] Accrued Maturity Date Monthly payments Accrues interest Promissory note Promissory note payable Related party advances Repayments on loan payable Interest expense Accrued interest Restricted stock units, vesting Issuances of Securities (Details) Number of units total awards outstanding, beginning Number of units granted Number of units exercised/released Number of units cancelled/forfeited Number of units total awards outstanding, ending Weighted average total awards outstanding, beginning Weighted average units granted Weighted average units exercised/released Weighted average units cancelled/forfeited Weighted average total awards outstanding, ending Award Date Axis Subsidiary Sale Of Stock Axis Class Of Financing Receivable Type Of Borrower Axis January 1, 2021 [Member] Officers And Directors [Member] Affiliated Investor [Member] Private Placement [Member] Non Affiliated Investor [Member] Consultants [Member] Related Party [Member] Board of Directors [Member] Common stock with a fair value Unrecognized compensation cost Common stock shares cancellations Stock based compensation expense Common stock, fair value Restricted stock unit, vested Stock-based compensation expense Common stock, shares issued for service rendered, shares Common stock, shares issued for service rendered, amount Common stock sold Cash proceeds Loss on settlement of debt [Gain (Loss) on Sale of Debt Investments] Common stock shares issued during the period Shares issued for settel accrued liability, shares Shares issued for settel accrued liability, amount Debt instrument, conversion of shares Common stock issued for conversion of convertible notes payable and accrued interest - related party, shares [Conversion of Stock, Shares Issued] Restricted stock units granted Litigation (Details Narrative) Former Chief Executive Officer and Chief Medical Advisor [Member] Lead Dog Capital LP [Member] Accrued Common stock shares issued Litigation settlement, shares issuable under agreement, fair value Compensatory damages Loss contingency damages sought, punitive damages Loss contingency damages sought, description Maxim Group LLC [Member] March 2021 [Member] Other income Former Officer [Member] CEO [Member] Description of installment Civil penalty accrue Common shares issued Received in advanced Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees. The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that por The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit). The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit). The total expense recognized in the period for promotion, public relations, and brand or product advertising. EX-101.CAL 8 ueec-20220331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 9 ueec-20220331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 10 ueec-20220331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover - shares
3 Months Ended
Mar. 31, 2022
May 10, 2022
Cover [Abstract]    
Entity Registrant Name UNITED HEALTH PRODUCTS, INC.  
Entity Central Index Key 0001096938  
Document Type 10-Q  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity Small Business true  
Entity Shell Company false  
Entity Emerging Growth Company false  
Entity Current Reporting Status Yes  
Document Period End Date Mar. 31, 2022  
Entity Filer Category Non-accelerated Filer  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2022  
Entity Common Stock Shares Outstanding   230,127,509
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 000-27781  
Entity Incorporation State Country Code NV  
Entity Tax Identification Number 84-1517723  
Entity Interactive Data Current Yes  
Entity Address City Or Town Henderson  
Entity Address State Or Province NV  
Entity Address Postal Zip Code 89052  
City Area Code 877  
Local Phone Number 358-3444  
Entity Address Address Line 1 10624 S. Eastern Ave., Suite A209  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Balance Sheets - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Current Assets    
Cash and Cash Equivalents $ 32,955 $ 21,799
Prepaid and other current assets 5,000 5,000
Total current assets 37,955 26,799
Patents, net 39,488 0
TOTAL ASSETS 77,443 26,799
Current Liabilities    
Accounts payable and accrued expenses 1,014,412 826,486
Accrued liabilities - related parties 138,616 3,207
Accrued litigation settlement 450,000 120,000
Promissory note payable 85,080 0
Loans payable - related parties 404,000 219,000
Total current liabilities 2,092,108 1,168,693
TOTAL LIABILITIES 2,092,108 1,168,693
Commitments and Contingencies 0 0
Stockholders' Equity (Deficit)    
Series A Convertible Preferred Stock - $.001 par value, 1,000,000 shares Authorized and 0 shares issued and outstanding 0 0
Common Stock - $.001 par value, 300,000,000 shares Authorized, 228,877,509 and 228,667,229 shares issued at March 31, 2022 and December 31, 2021 228,877 228,667
Additional Paid-In Capital 71,109,164 71,017,881
Accumulated Deficit (73,352,706) (72,388,442)
Total Stockholders' Equity (Deficit) (2,014,665) (1,141,894)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) $ 77,443 $ 26,799
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2022
Dec. 31, 2021
Common stock, shares par value $ 0.001 $ 0.001
Common stock, shares authorized 300,000,000 300,000,000
Common stock, shares issued 228,877,509 228,667,229
Common stock, shares outstanding 228,877,509 228,667,229
Series A Convertible Preferred Stock [Member]    
Preferred Stock, shares par value $ 0.001 $ 0.001
Preferred Stock, shares authorized 1,000,000 1,000,000
Preferred Stock, shares issued 0 0
Preferred Stock, shares outstanding 0 0
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Condensed Statements of Operations (Unaudited)    
Revenues $ 0 $ 59
Cost of goods sold 0 25
Gross profit 0 34
Operating Costs and Expenses    
Selling, general and administrative expenses 902,146 26,647,045
Research and development 52,355 58,180
Total Operating Expenses 954,501 26,705,225
Income/(Loss) from Operations (954,501) (26,705,191)
Other income (expense)    
Interest expense (80) (221,226)
Interest expense - related party (8,808) (389,804)
Loss on settlement of debt (875) (35,190)
Other income 0 304,273
Total other income (expense) (9,763) (341,947)
Net Income/(Loss) $ (964,264) $ (27,047,138)
Net Loss per common share:    
Basic and diluted $ (0.00) $ (0.12)
Weighted average number of shares outstanding 228,726,869 222,059,641
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Statement of Stockholders Equity (Unaudited) - USD ($)
Total
Common Stock [Member]
Additional Paid-In Capital
Accumulated Deficit
Balance, shares at Dec. 31, 2020   189,357,090    
Balance, amount at Dec. 31, 2020 $ (953,262) $ 189,357 $ 40,696,640 $ (41,839,259)
Beneficial conversion feature 234,912 $ 0 234,912 0
Issuance of common stock for services, shares   100,000    
Issuance of common stock for services, amount 111,000 $ 100 110,900 0
Sale of common stock, shares   125,000    
Sale of common stock, amount 100,000 $ 125 99,875 0
Cancellation of common stock, shares   (117,647)    
Cancellation of common stock, amount 0 $ (117) 117 0
Stock-based compensation, shares   33,930,000    
Stock-based compensation, amount 26,170,421 $ 33,930 26,136,491 0
Common stock issued to settle accrued liabilities - related party, shares   152,835    
Common stock issued to settle accrued liabilities - related party, amount 161,964 $ 153 161,811 0
Common stock issued to settle related party advances, shares   25,000    
Common stock issued to settle related party advances, amount 26,750 $ 25 26,725 0
Common stock issued for conversion of convertible notes payable and accrued interest, shares   1,047,139    
Common stock issued for conversion of convertible notes payable and accrued interest, amount 560,071 $ 1,047 559,024 0
Common stock issued for conversion of convertible notes payable and accrued interest - related party, shares   1,353,111    
Common stock issued for conversion of convertible notes payable and accrued interest - related party, amount 676,555 $ 1,353 675,202 0
Net Loss (27,047,138) $ 0 0 (27,047,138)
Balance, shares at Mar. 31, 2021   225,972,528    
Balance, amount at Mar. 31, 2021 41,273 $ 225,973 68,701,697 (68,886,397)
Balance, shares at Dec. 31, 2021   228,667,229    
Balance, amount at Dec. 31, 2021 (1,141,894) $ 228,667 71,017,881 (72,388,442)
Issuance of common stock for services, shares   20,000    
Issuance of common stock for services, amount 10,200 $ 20 10,180 0
Sale of common stock, shares   184,028    
Sale of common stock, amount 77,292 $ 184 77,108 0
Net Loss (964,264) $ 0 0 (964,264)
Common stock issued to settle accounts payable and accrued liabilities, shares   6,252    
Common stock issued to settle accounts payable and accrued liabilities, amount 4,001 $ 6 3,995 0
Balance, shares at Mar. 31, 2022   228,877,509    
Balance, amount at Mar. 31, 2022 $ (2,014,665) $ 228,877 $ 71,109,164 $ (73,352,706)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash Flows from Operating Activities:    
Net (Loss) $ (964,264) $ (27,047,138)
Adjustments to Reconcile net (loss) to Net Cash Used In Operating Activities:    
Stock for services and compensation 10,200 26,281,421
Amortization expense 1,012 0
Amortization of debt discount 0 604,521
Loss on settlement of debt 875 35,190
Changes in assets and liabilities:    
Inventory 0 25
Prepaid and other current assets 0 (5,000)
Subscription Receivable 0 (50,000)
Accounts payable and accrued expenses 191,052 (46,312)
Accrued liabilities - related party 135,409 116,805
Accrued litigation settlement 430,000 0
Net Cash Used In Operating Activities (195,716) (110,488)
Cash Flows from Investing Activities:    
Purchase of intangible assets (40,500) 0
Net Cash Used in Investing Activities (40,500) 0
Cash Flows from Financing Activities:    
Proceeds from related party 185,000 20,000
Repayments on loan payable (14,920) 0
Proceeds from sale of common stock 77,292 100,000
Proceeds from convertible notes payable 0 115,000
Cash flow provided by financing activities 247,372 235,000
Increase in Cash and Cash Equivalents 11,156 124,512
Cash and Cash Equivalents - Beginning of period 21,799 46,076
CASH AND CASH EQUIVALENTS - END OF PERIOD 32,955 170,588
Supplemental cash flow information:    
Cash paid for interest 80 0
Cash paid for income taxes 0 0
Non-cash Investing & Financing Activities:    
Cancellation of common stock 0 117
Conversion of convertible notes payable and accrued interest - related party to convertible notes payable and accrued interest 0 176,502
Common stock issued for conversion of convertible notes payable and accrued interest - related party 0 676,555
Common stock issued for conversion of convertible notes payable and accrued interest 0 560,071
Conversion of accounts payable to convertible notes payable 0 90,000
Common stock issued to settle related party advances 0 26,750
Common stock issued to settle accrued liabilities - related party 0 161,964
Conversion of accrued liabilities - related party to convertible notes payable - related party 0 112,500
Common stock issued to settle accrued liabilities 3,126 0
Accrued litigation settlement paid with loan payable 100,000 0
Debt discount related to beneficial conversion feature $ 0 $ 234,912
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Organization and Basis of Preparation
3 Months Ended
Mar. 31, 2022
Organization and Basis of Preparation  
Organization and Basis of Preparation

Note 1. Organization and Basis of Preparation

 

United Health Products, Inc. (the “Company”) develops, manufactures, and markets a patented hemostatic gauze for the healthcare and wound care sectors. Our gauze product, HemoStyp®, is a neutralized, oxidized, regenerated cellulose (“NORC”) derived from cotton and designed to absorb exudate/drainage from superficial wounds and help control bleeding. We are in the process of seeking regulatory approval to sell our Hemostyp product line into the U.S. Class III and European Union CE Mark surgical markets.

 

The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on April 1, 2022.

 

In the opinion of management, all adjustments, which are of a normal recurring nature, considered necessary for the fair presentation of financial statements for the interim period, have been included.

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Significant Accounting Policies
3 Months Ended
Mar. 31, 2022
Significant Accounting Policies  
Significant Accounting Policies

Note 2. Significant Accounting Policies

 

Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred recurring net losses, negative working capital and operations have not provided cash flows. Additionally, the Company does not currently have sufficient revenue producing operations to cover its operating expenses and meet its current obligations. In view of these matters, there is substantial doubt about the Company’s ability to continue as a going concern. The Company intends to finance its future development activities and its working capital needs largely from the sale of equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

On March 11, 2020, the World Health Organization declared the outbreak of a coronavirus (COVID-19) as a pandemic. As a result, economic uncertainties have arisen which have the potential to negatively impact the Company’s ability to raise funding and to pursue is business objectives. Other factors that carry financial implications for the Company could occur although the potential impacts are unknown at this time.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid debt investments purchased with a maturity of three months or less to be cash equivalents.

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reported period. Changes in the economic environment, financial markets, as well as in the healthcare industry, and any other parameters used in determining these estimates, could cause actual results to differ.

 

 Revenue Recognition

 

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the sale of its HemoStyp product by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.

 

The Company receives orders for its HemoStyp products directly from its customers. Revenues are recognized based on the agreed upon sales or transaction price with the customer when control of the promised goods are transferred to the customer. The transfer of goods to the customer and satisfaction of the Company’s performance obligation will occur either at the time when products are shipped or when the products arrive and are received by the customer. No discounts are currently offered by the Company. The Company does not provide an estimate for returns as there is no anticipation for any returns in the normal course of business.

 

Trade Accounts Receivable and Concentration Risk

 

We record accounts receivable at the invoiced amount and we do not charge interest. We review the accounts receivable by amounts due from customers that are past due, to identify specific customers with known disputes or collectability issues. In determining the amount of the reserve, we make judgments about the creditworthiness of significant customers based on ongoing credit evaluations. We will also maintain a sales allowance to reserve for potential credits issued to customers. We will determine the amount of the reserve based on historical credit issued.

 

There were no provisions for doubtful accounts recorded at March 31, 2022 and December 31, 2021. The Company recorded $0 and $0 in bad debt expense for the three month periods ended March 31, 2022 and 2021, respectively.

 

Stock Based Compensation

 

The Company accounts for share-based compensation under the provisions of ASC 718, Compensation-Stock Compensation. Under the fair value recognition provisions, stock-based compensation expense is measured at the fair value of the consideration received, or the fair value of the equity instruments issued, or liabilities incurred, whichever is more reliably measured. Share-based compensation for all stock-based awards to employees and directors is recognized as an expense over the requisite service period, which is generally the vesting period.

 

The Company accounts for stock compensation arrangements with non-employees in accordance with Accounting Standard Update (ASU) 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which requires that such equity instruments are recorded at the value on the grant date.

 

Per Share Information

 

Basic earnings per share are calculated using the weighted average number of common shares outstanding for the period presented. Diluted earnings per share is computed using the weighted-average number of common shares and, if dilutive, potential common shares outstanding during the period. The dilutive effect of potential common shares is not reflected in diluted earnings per share because the Company incurred net losses for the three months ended March 31, 2022 and 2021 and the effect of including these potential common shares in the net loss per share calculations would be anti-dilutive.

The total potential common shares as of March 31, 2022 included 28,190,000 of restricted stock units. The total potential common shares as of March 31, 2021 includes 27,400,000 of restricted stock units, and 35,294 shares for convertible loans payable - related party.

 

Patents

 

Patents are stated on the balance sheet at cost. Costs, such as filing fees with patent granting agencies and legal fees directly relating to those filings, incurred to file patent applications were capitalized when the Company believed that there was a high likelihood that the patent would be issued and there would be future economic benefit associated with the patent. These costs were amortized from the date of the patent application on a straight-line basis over the estimated useful life of 10 years. All costs associated with any abandoned patent applications are expensed.

 

Accumulated amortization as of March 31, 2022 and December 31, 2021 was $1,012 and $0, respectively. Amortization expense for the three months ended March 31, 2022 and 2021 was $1,012 and $0, respectively.

 

Future Amortization Expense

 

Year

 

Amount

 

2022 (remaining)

 

$3,038

 

2023

 

 

4,050

 

2024

 

 

4,050

 

2025

 

 

4,050

 

2026

 

 

4,050

 

Thereafter

 

 

20,250

 

 

 

$39,488

 

 

Impairment of Long-lived Assets

 

The Company applies the provisions of ASC 360, Property, Plant and Equipment, where applicable to all long-lived assets. ASC 360 addresses accounting and reporting for impairment and disposal of long-lived assets. The Company periodically evaluates the carrying value of long-lived assets to be held and used in accordance with ASC 360. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal.

 

When long-lived assets are sold or retired, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss is included in the results of operations. During the three months ended March 31, 2022 and 2021, the Company determined no impairment was required.

 

New Accounting Pronouncements

 

The Company considers all new pronouncements and management has determined that there have been no recently adopted or issued accounting standards that had or will have a material impact on its financial statements.

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions
3 Months Ended
Mar. 31, 2022
Related Party Transactions  
Related Party Transactions

Note 3. Related Party Transactions

 

Loans payable - related parties

 

As of December 31, 2021, 21, Brian Thom, Chief Executive Officer had a loan payable balance of $175,000.

 

During the three months ended March 31, 2022, Mr. Thom loaned the Company $165,000 to pay for operating expenses. As of March 31, 2022, $340,000 is owed to Mr. Thom. The loans have an interest rate of 10% and have a maturity date of December 31, 2022.

 

As of December 31, 2021, Lou Schiliro, the former Chief Operating Officer, had a loan payable balance of $44,000.

 

During the three months ended March 31, 2022, Mr. Schiliro, loaned the Company $20,000 to pay for operating expenses. As of March 31, 2022, $64,000 is owed to Mr. Schiliro. The loans have an interest rate of 10% and have a maturity date of December 31, 2022.

 

Interest expense – related party on the above loans was $8,808 during the three months ended March 31, 2022. Accrued interest – related party as of March 31, 2022 and December 31, 2021 was $11,116 and $2,308, respectively.

 

Accrued liabilities – related parties

 

As of March 31, 2022 and December 31, 2021, $45,000 and $899 was owed to Mr. Thom for accrued compensation and reimbursable expenses, respectively.

 

As of March 31, 2022 and December 31, 2021, $45,000 and $0 was owed to Mr. Schiliro for accrued compensation, respectively.

 

As of March 31, 2022 and December 31, 2021, $37,500 and $0 was owed to Kristofer Heaton, the Principal Financial Officer, for accrued compensation, respectively.

 

Equity transactions

 

Per the vesting schedules of certain of the Company’s amended RSU Agreements, on January 1, 2021, 6,760,000 shares of common stock were issued to Mr. Douglas Beplate, former Chairman of the Board, 2,000,000 shares of common stock were issued to Mr. Schiliro and 100,000 shares of common stock were issued to Mr. Heaton.

On January 6, 2021, the Board of Directors approved the second amendment to the RSU Agreement between the Company and Mr. Beplate in conjunction with Mr. Beplate’s retirement from his day-to-day management role with the Company. The amendment accelerated the vesting and immediately settled his remaining RSUs by issuing 21,970,000 shares of common stock. Further, as a bonus in recognition of Mr. Beplate’s service to the Company and in recruitment of new executive management, the Company issued to Mr. Beplate an additional 2,000,000 shares of common stock. The Company recorded $26,127,300 of stock-based compensation expense during the three months ended March 31, 2021 related to the accelerated vesting of these RSU’s and issuance of common stock.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Promissory Note Payable
3 Months Ended
Mar. 31, 2022
Related Party Transactions  
Promissory Note Payable

Note 4. Promissory Note Payable

 

During the three months ended March 31, 2022, the Company reached a settlement agreement related to Patterson’s counterclaim (see Note 6). The Company agreed to pay $120,000 which had previously been accrued as of December 31, 2021.

 

The Company paid $20,000 of the settlement and entered into a $100,000 promissory note with its legal counsel to fund the payment of the remaining balance. The Company paid $14,920 of principal and $80 in interest expense leaving a principal balance of $85,080 and accrued interest of $0 as of March 31, 2022. The note accrues interest at 1% and requires monthly payments of $9,136 until the balance is paid in full.

 

The promissory note is secured by 200,000 shares of restricted common stock which would have demand registration rights and the Company would file a registration statement within 45 days of the request.

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Issuances of Securities
3 Months Ended
Mar. 31, 2022
Issuances of Securities  
Issuances of Securities

Note 5. Issuances of Securities

 

Share issuances 2021

 

During the three months ended March 31, 2021, a total of 31,930,000 shares of common stock were issued to officers, directors and various consultants related to vesting of RSU’s with a total stock-based compensation cost of $23,990,421, 2,000,000 shares of common stock were issued to Mr. Beplate as a stock bonus with a stock-based compensation cost of $2,180,000, 125,000 shares of common stock were sold to an affiliated investor in a private placement for total cash proceeds of $100,000, 100,000 shares of common stock were issued for settlement of a business consulting agreement with a fair value of $111,000, 25,000 shares of commons stock were issued to settle $20,000 of related party advances, 152,835 shares of common stock were issued to settle $133,523 of accrued liabilities – related party, 1,047,139 shares of common stock were issued due to the conversion of convertible notes payable and accrued interest, 1,353,111 shares of common stock were issued due to the conversion of convertible notes payable and accrued interest – related party and 117,647 shares of common stock were cancelled.

 

Share issuances 2022

 

During the three months ended March 31, 2022, 184,028 shares of common stock were sold to non-affiliated investors in a private placement for total cash proceeds of $77,292, 6,252 shares of commons stock were issued to settle $3,126 of accrued liabilities resulting in a loss on settlement of debt of $875 and 20,000 shares of common stock with a fair value of $10,200 were issued for legal services.

 

Restricted stock units

 

As discussed in Note 3, during the year ended December 31, 2020 the Board of Directors approved amendments to its March 25, 2019 RSU Agreement for certain management and consultants to the Company.

 

The amendment resulted in 9,960,000 of the RSU’s vesting on January 1, 2021. The fair value of the 9,960,000 RSU’s. The compensation expense was being amortized on a straight-line basis from the date of the amendment through January 1, 2021 which is the vesting date. Stock-based compensation of $43,121 was recognized as expense during the three months ended March 31, 2021.

 

On January 6, 2021, the Board of Directors approved the second amendment to the Restricted Stock Unit Agreement between the Company and Mr. Beplate, former Chief Executive Officer and former Chairman of the Board, in conjunction with Mr. Beplate’s retirement from his day-to-day management role with the Company. The amendment accelerated the vesting and immediately settled his remaining RSUs by issuing 21,970,000 shares of common stock.

Per ASC 718-20-35, the change in vesting conditions resulted in a modification of the stock-based compensation awards. The modification is considered a Type III modification as described in ASC 718-20-55 and resulted in recording $23,947,300 of stock-based compensation expense which was the fair value of the shares on the date of the modification.

 

Activity related to our restricted stock units during the three months ended March 31, 2022 was as follows:

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

Average

 

 

 

 

 

 

Grant

 

 

 

Number of

 

 

Date Fair

 

 

 

Units

 

 

Value

 

Total awards outstanding at December 31, 2021

 

 

28,190,000

 

 

$0.96

 

Units granted

 

 

-

 

 

$-

 

Units Exercised/Released

 

 

-

 

 

$-

 

Units Cancelled/Forfeited

 

 

-

 

 

$-

 

Total awards outstanding at March 31, 2022

 

 

28,190,000

 

 

$0.96

 

 

Management is unable to predict if or when a Covered Transaction or Triggering Event under the RSU Agreements governing the restricted stock units will occur and as of March 31, 2022, there was $27,017,200 of unrecognized compensation cost related to unvested restricted stock unit awards.  

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Litigation
3 Months Ended
Mar. 31, 2022
Litigation  
Litigation

Note 6. Litigation

 

Philip Forman, who served as Chairman, a director, Chief Executive Officer and Chief Medical Advisor of the Company at various times between 2011 and October 2015, filed a lawsuit against the Company and our then-Chief Executive Officer, Douglas Beplate, in the United States District Court of the District of Nevada. The plaintiff has claimed, among other things: that the June 25, 2015 Amendment to his November 10, 2014 Employment Agreement with the Company, which terminated the Employment Agreement on October 1, 2015, is not enforceable due to lack of consideration; that a July 22, 2015 Stock Purchase Agreement pursuant to which the plaintiff sold Company shares issued to him under the Amendment to a third a party is unenforceable (despite the fact that all payment for the shares under the Stock Purchase Agreement was made); that the plaintiff’s 2014 Employment Agreement remains valid and that he is entitled to cash and stock compensation under that Employment Agreement (without giving regard to the Amendment); and that the Company and Mr. Beplate defrauded the plaintiff relating to the foregoing. The plaintiff is seeking declaratory judgment regarding the parties’ relative rights under the Employment Agreement, the Amendment and the Stock Purchase Agreement; money damages of no less than $2,795,000; and punitive damages of $8,280,000. The Company filed a motion to dismiss the plaintiff’s claims which was denied on March 19, 2020. On May 5, 2021, the plaintiff provided a deposition as instructed by the Court, subsequent to which the Company filed a motion for dismissal of this proceeding. On February 14, 2022, the Court issued an Order which declared the Amendment to be unenforceable and thus the terms of the original Employment Agreement to remain in effect. The Order also noted that the Company is not a party to the Stock Purchase Agreement, and the Employment Agreement does not constitute a prior agreement that could have been superseded by the Stock Purchase Agreement. The parties are currently engaged in settlement discussions.

 

In 2018 an action was commenced in the United States District Court Southern District of New York entitled JEC Consulting Associates, LLC. Liquidator of Lead Dog Capital LP against United Health Products t/k/a United EcoEnergy Corp and Douglas K. Beplate under Docket Number 18-cv-1139 (ER). The third-party action sought to remove a restrictive legend from a particular stock certificate for Three Million Fifty Thousand (3,050,000) shares and declare the shares to be free trading. The third-party plaintiff alleges that the Company and Mr. Beplate refused to have the restrictive legend on the stock certificate removed under Rule 144 and sought compensatory and punitive damages. The Federal court issued an order that the Securities Exchange Commission should review the claim before the District Court renders a final ruling. Discovery appears to be substantially complete and settlement discussions between the third-party plaintiff and the Company have been initiated. On April 22, 2022 the parties entered in a Settlement Agreement wherein the Company would agree to allow the removal of the restrictive legend as permitted under applicable securities laws and distribution of the shares to affiliates of the plaintiffs. Under the Settlement Agreement the Company will make no payments other than to pay expenses related to its own legal counsel.

Due to uncertainties inherent in litigation, we cannot predict the outcome of the above legal proceedings.

 

The Company has commenced the following legal proceedings:

 

On February 7, 2020, the Company filed the Original Petition for Fraud and Breach of Contract in the Texas District Court for the 215th Judicial District of Harris County against defendants Patterson Companies Inc., Patterson Management, L.P., Patterson Veterinary, Inc. and Patterson Logistics Services, Inc., and Animal Health International, Inc. On March 5, 2020, the defendants removed the case to U.S. District Court for Southern District of Texas. The defendants filed their answer in federal court on March 12, 2020. The original August 25, 2020 pretrial deadlines were extended. On January 18, 2022, the Company’s claims were dismissed, with prejudice, by the court. On February 9, 2022, the Company and Patterson reached an agreement on settlement of Patterson’s counterclaim. The Company agreed to pay $120,000 which was accrued as of December 31, 2021. The $120,000 settlement payment was paid in full in February 2022.

 

In August 2020, United Health Products filed suit against its former auditors, Haynie & Company, in Utah State Court, asserting claims related to professional negligence and breach of fiduciary duty. Haynie & Company has denied the allegations. Discovery is largely complete and the parties have each submitted a report by their respective expert witness to the Court.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Other Income
3 Months Ended
Mar. 31, 2022
Other income (expense)  
Other income

Note 7. Other Income

 

The Company received payment of $304,273 from Maxim Group LLC, as full and final settlement of its previously disclosed arbitration between the Company and Maxim that was settled in December 2019. The $304,273 was recorded as other income in the Statement of Operations during the three months ended March 31, 2021. 

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Subsequent Event
3 Months Ended
Mar. 31, 2022
Subsequent Event  
Subsequent Events

Note 8. Subsequent Events

 

The Company has evaluated events from March 31, 2022, through the date whereupon the financial statements were issued and has determined that there are no material events that need to be disclosed except as follows:

 

In connection with the Securities and Exchange Commission’s investigation against the Company, Douglas Beplate, the former Chief Executive Officer and Chairman and a former director of the Company, and Louis Schiliro, the former Chief Operating Officer and a former director of the Company, concerning possible violations of certain provisions of the Securities Act of 1933 and the Securities Exchange Act of 1934, the Commission’s Enforcement Division has presented proposed settlement terms which the Enforcement Division has indicated it would recommend to the Commission to resolve the matter as to the Company, if acceptable to the Company. The investigation was previously reported by the Company in its prior periodic reports including its Annual Report for the year ended December 31, 2021 under Item 1A “Risk Factors”.

The proposed resolution terms of the investigation presented by the Commission would include a consent judgment against the Company on the following terms, among others, without the Company admitting or denying the Commission’s allegations:

 

 

·

The Company being permanently enjoined from violating: Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 under the Exchange Act; Section 17(a) of the Securities Act of 1933; Section 13(a) of the Exchange Act and Rules 12b-20, 13a-1 and 13a-13 under the Exchange Act; Section 13(b)(2)(A) of the Exchange Act; and Section 13(b)(2)(B) of the Exchange Act.

 

 

 

 

·

The Company being required to pay a civil penalty of $450,000, payable in four installments as follows: $50,000 upon the entry of the judgment; $100,000 within 90 days of the entry of the judgment; $150,000 within 180 days of the entry of the judgment; and $150,000 within 270 days of the entry of the judgment, plus statutory interest on payments made after 30 days of the entry of the judgment pursuant to U.S.C. Section 1961.

  

Additionally, the Company’s consent would include the Company’s agreement not to take any action or make any public statement denying any allegations in the Commission’s complaint or creating the impression that the complaint is without factual basis; and not to make any public statement to the effect that the Company does not admit the allegations in the complaint without also stating that the Company does not deny the allegations.

 

The $450,000 civil penalty has been accrued as of March 31, 2022.

 

The Company received a total of $50,000 in advances from its Chief Executive Officer.

 

The Company issued a total of 1,250,000 shares of common stock to officers and various consultants for accrued compensation and services provided in lieu of cash salary payments due under their respective consulting agreements.

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2022
Significant Accounting Policies  
Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred recurring net losses, negative working capital and operations have not provided cash flows. Additionally, the Company does not currently have sufficient revenue producing operations to cover its operating expenses and meet its current obligations. In view of these matters, there is substantial doubt about the Company’s ability to continue as a going concern. The Company intends to finance its future development activities and its working capital needs largely from the sale of equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

On March 11, 2020, the World Health Organization declared the outbreak of a coronavirus (COVID-19) as a pandemic. As a result, economic uncertainties have arisen which have the potential to negatively impact the Company’s ability to raise funding and to pursue is business objectives. Other factors that carry financial implications for the Company could occur although the potential impacts are unknown at this time.

Cash and Cash Equivalents

The Company considers all highly liquid debt investments purchased with a maturity of three months or less to be cash equivalents.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reported period. Changes in the economic environment, financial markets, as well as in the healthcare industry, and any other parameters used in determining these estimates, could cause actual results to differ.

Revenue Recognition

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the sale of its HemoStyp product by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.

 

The Company receives orders for its HemoStyp products directly from its customers. Revenues are recognized based on the agreed upon sales or transaction price with the customer when control of the promised goods are transferred to the customer. The transfer of goods to the customer and satisfaction of the Company’s performance obligation will occur either at the time when products are shipped or when the products arrive and are received by the customer. No discounts are currently offered by the Company. The Company does not provide an estimate for returns as there is no anticipation for any returns in the normal course of business.

Trade Accounts Receivable and Concentration Risk

We record accounts receivable at the invoiced amount and we do not charge interest. We review the accounts receivable by amounts due from customers that are past due, to identify specific customers with known disputes or collectability issues. In determining the amount of the reserve, we make judgments about the creditworthiness of significant customers based on ongoing credit evaluations. We will also maintain a sales allowance to reserve for potential credits issued to customers. We will determine the amount of the reserve based on historical credit issued.

 

There were no provisions for doubtful accounts recorded at March 31, 2022 and December 31, 2021. The Company recorded $0 and $0 in bad debt expense for the three month periods ended March 31, 2022 and 2021, respectively.

Stock Based Compensation

The Company accounts for share-based compensation under the provisions of ASC 718, Compensation-Stock Compensation. Under the fair value recognition provisions, stock-based compensation expense is measured at the fair value of the consideration received, or the fair value of the equity instruments issued, or liabilities incurred, whichever is more reliably measured. Share-based compensation for all stock-based awards to employees and directors is recognized as an expense over the requisite service period, which is generally the vesting period.

 

The Company accounts for stock compensation arrangements with non-employees in accordance with Accounting Standard Update (ASU) 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which requires that such equity instruments are recorded at the value on the grant date.

Per Share Information

Basic earnings per share are calculated using the weighted average number of common shares outstanding for the period presented. Diluted earnings per share is computed using the weighted-average number of common shares and, if dilutive, potential common shares outstanding during the period. The dilutive effect of potential common shares is not reflected in diluted earnings per share because the Company incurred net losses for the three months ended March 31, 2022 and 2021 and the effect of including these potential common shares in the net loss per share calculations would be anti-dilutive.

The total potential common shares as of March 31, 2022 included 28,190,000 of restricted stock units. The total potential common shares as of March 31, 2021 includes 27,400,000 of restricted stock units, and 35,294 shares for convertible loans payable - related party.
Patents Patents are stated on the balance sheet at cost. Costs, such as filing fees with patent granting agencies and legal fees directly relating to those filings, incurred to file patent applications were capitalized when the Company believed that there was a high likelihood that the patent would be issued and there would be future economic benefit associated with the patent. These costs were amortized from the date of the patent application on a straight-line basis over the estimated useful life of 10 years. All costs associated with any abandoned patent applications are expensed.

 

Accumulated amortization as of March 31, 2022 and December 31, 2021 was $1,012 and $0, respectively. Amortization expense for the three months ended March 31, 2022 and 2021 was $1,012 and $0, respectively.

 

Future Amortization Expense

 

Year

 

Amount

 

2022 (remaining)

 

$3,038

 

2023

 

 

4,050

 

2024

 

 

4,050

 

2025

 

 

4,050

 

2026

 

 

4,050

 

Thereafter

 

 

20,250

 

 

 

$39,488

 

Impairment of Long-lived Assets

The Company applies the provisions of ASC 360, Property, Plant and Equipment, where applicable to all long-lived assets. ASC 360 addresses accounting and reporting for impairment and disposal of long-lived assets. The Company periodically evaluates the carrying value of long-lived assets to be held and used in accordance with ASC 360. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal.

 

When long-lived assets are sold or retired, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss is included in the results of operations. During the three months ended March 31, 2022 and 2021, the Company determined no impairment was required.

New Accounting Pronouncements

The Company considers all new pronouncements and management has determined that there have been no recently adopted or issued accounting standards that had or will have a material impact on its financial statements.

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2022
Significant Accounting Policies  
Schedule of Future Amortization Expense

Year

 

Amount

 

2022 (remaining)

 

$3,038

 

2023

 

 

4,050

 

2024

 

 

4,050

 

2025

 

 

4,050

 

2026

 

 

4,050

 

Thereafter

 

 

20,250

 

 

 

$39,488

 

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Issuances of Securities (Tables)
3 Months Ended
Mar. 31, 2022
Issuances of Securities  
Schedule of Restricted stock units

 

 

 

 

 

Weighted

 

 

 

 

 

 

Average

 

 

 

 

 

 

Grant

 

 

 

Number of

 

 

Date Fair

 

 

 

Units

 

 

Value

 

Total awards outstanding at December 31, 2021

 

 

28,190,000

 

 

$0.96

 

Units granted

 

 

-

 

 

$-

 

Units Exercised/Released

 

 

-

 

 

$-

 

Units Cancelled/Forfeited

 

 

-

 

 

$-

 

Total awards outstanding at March 31, 2022

 

 

28,190,000

 

 

$0.96

 

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Significant Accounting Policies (Details)
Mar. 31, 2022
USD ($)
Significant Accounting Policies  
2022 (remaining) $ 3,038
2023 4,050
2024 4,050
2025 4,050
2026 4,050
Thereafter 20,250
Future Amortization Expense $ 39,488
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Accumulated amortization $ 1,012   $ 0
Bad debt expense 0 $ 0  
Amortization expense $ 1,012 $ 0  
Description of patent straight-line basis over the estimated useful life of 10 years    
Restricted Stock Units [Member]      
Convertible loans Payable shares, related party   35,294  
Potential antidilutive shares 28,190,000 27,400,000  
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Jan. 06, 2021
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Loan from related party   $ 185,000 $ 20,000  
Maturity Date   Dec. 31, 2021    
Operating expenses   $ 954,501 26,705,225  
Stock based compensation   $ 10,200 $ 26,281,421  
Kristofer Heaton [Member]        
Restricted stock units granted   100,000    
Amount owed   $ 0    
Reimbursable expenses   37,500   $ 0
Accrued compensation   $ 37,500   0
Additional RSU's issued   100,000    
Payment of compensation       0
Douglas Beplate [Member]        
Restricted stock units granted   6,760,000    
RSU granted to officers, directors and consultants   2,000,000    
Brian Thom [Member]        
Amount owed   $ 340,000    
Interest Rate   10.00%    
Maturity Date   Dec. 31, 2022    
Reimbursable expenses   $ 45,000   899
Accrued compensation   45,000   899
Operating expenses   165,000    
Convertible loans payable - related parties       175,000
Mr. Beplate [Member]        
Restricted stock units granted 21,970,000      
Stock based compensation $ 26,127,300      
Common stock share issued 2,000,000      
Converted loans payable and accrued liabilities   100,000    
Louis Schiliro [Member]        
Loan from related party   $ 8,808    
Restricted stock units granted   2,000,000    
Amount owed   $ 64,000    
Interest Rate   10.00%    
Maturity Date   Dec. 31, 2022    
Reimbursable expenses   $ 45,000   0
Accrued compensation   45,000   0
Operating expenses   20,000    
Accrued interest   $ 11,116   2,308
Remaining balance       $ 44,000
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Promissory Note Payable (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Accrued $ 120,000   $ 120,000
Maturity Date Dec. 31, 2021    
Promissory note payable $ 85,080   $ 0
Related party advances 185,000 $ 20,000  
Repayments on loan payable 14,920 0  
Interest expense 80 $ 221,226  
Legal Counsel [Member]      
Monthly payments $ 9,136    
Accrues interest 1.00%    
Promissory note $ 100,000    
Promissory note payable 85,080    
Related party advances 20,000    
Repayments on loan payable 14,920    
Interest expense 80    
Accrued interest $ 0    
Restricted stock units, vesting 200,000    
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Issuances of Securities (Details)
3 Months Ended
Mar. 31, 2022
shares
Issuances of Securities (Details)  
Number of units total awards outstanding, beginning 28,190,000
Number of units granted 0
Number of units exercised/released 0
Number of units cancelled/forfeited 0
Number of units total awards outstanding, ending 28,190,000
Weighted average total awards outstanding, beginning 0.96
Weighted average units granted 0
Weighted average units exercised/released 0
Weighted average units cancelled/forfeited 0
Weighted average total awards outstanding, ending 0.96
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Issuances of Securities (Details Narrative) - USD ($)
3 Months Ended
Jan. 06, 2021
Jan. 06, 2021
Mar. 31, 2022
Mar. 31, 2021
Common stock with a fair value     $ 20,000  
Unrecognized compensation cost     27,017,200  
Common stock shares cancellations       117,647
Stock based compensation expense     23,947,300  
Common stock, fair value     10,200  
Board of Directors [Member]        
Stock-based compensation expense     $ 23,947,300  
Restricted stock units granted   21,970,000    
Mr. Beplate [Member]        
Common stock, shares issued for service rendered, shares       2,000,000
Common stock, shares issued for service rendered, amount       $ 2,180,000
Restricted stock units granted 21,970,000      
Officers And Directors [Member]        
Common stock, shares issued for service rendered, shares       31,930,000
Common stock, shares issued for service rendered, amount       $ 23,990,421
Affiliated Investor [Member] | Private Placement [Member]        
Common stock, shares issued for service rendered, shares       125,000
Common stock, shares issued for service rendered, amount       $ 100,000
Non Affiliated Investor [Member] | Private Placement [Member]        
Common stock, shares issued for service rendered, shares     6,252 100,000
Common stock, shares issued for service rendered, amount     $ 3,126 $ 100,000
Common stock sold     184,028  
Cash proceeds     $ 77,292  
Loss on settlement of debt     $ 875  
Consultants [Member]        
Cash proceeds       111,000
Related Party [Member]        
Cash proceeds       $ 20,000
Common stock shares issued during the period       25,000
Shares issued for settel accrued liability, shares       152,835
Shares issued for settel accrued liability, amount       $ 133,523
Debt instrument, conversion of shares       1,047,139
Common stock issued for conversion of convertible notes payable and accrued interest - related party, shares       1,353,111
January 1, 2021 [Member]        
Restricted stock unit, vested     9,960,000  
Stock-based compensation expense       $ 43,121
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Litigation (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Accrued $ 120,000 $ 120,000
Common stock shares issued 228,877,509 228,667,229
Litigation settlement, shares issuable under agreement, fair value $ 120,000  
Lead Dog Capital LP [Member]    
Loss contingency damages sought, description in the United States District Court Southern District of New York entitled JEC Consulting Associates, LLC. Liquidator of Lead Dog Capital LP against United Health Products t/k/a United EcoEnergy Corp and Douglas K. Beplate under Docket Number 18-cv-1139 (ER). The third-party action sought to remove a restrictive legend from a particular stock certificate for Three Million Fifty Thousand (3,050,000) shares and declare the shares to be free trading  
Former Chief Executive Officer and Chief Medical Advisor [Member]    
Compensatory damages $ 2,795,000  
Loss contingency damages sought, punitive damages $ 8,280,000  
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Other Income (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Other income $ 0 $ 304,273
Maxim Group LLC [Member]    
Other income 304,273  
Maxim Group LLC [Member] | March 2021 [Member]    
Other income $ 304,273  
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Subsequent Events (Details Narrative)
3 Months Ended
Mar. 31, 2022
USD ($)
shares
Description of installment The Company being required to pay a civil penalty of $450,000, payable in four installments as follows: $50,000 upon the entry of the judgment; $100,000 within 90 days of the entry of the judgment; $150,000 within 180 days of the entry of the judgment; and $150,000 within 270 days of the entry of the judgment, plus statutory interest on payments made after 30 days
Civil penalty accrue $ 450,000
Former Officer [Member]  
Common shares issued | shares 1,250,000
CEO [Member]  
Received in advanced $ 50,000
XML 37 ueec_10q_htm.xml IDEA: XBRL DOCUMENT 0001096938 2022-01-01 2022-03-31 0001096938 ueec:CEOMember 2022-01-01 2022-03-31 0001096938 ueec:FormerOfficerMember 2022-01-01 2022-03-31 0001096938 ueec:MaximGroupLLCMember 2022-01-01 2022-03-31 0001096938 ueec:MaximGroupLLCMember ueec:MarchTwoThousandTwentyOneMember 2022-01-01 2022-03-31 0001096938 ueec:LeadDogCapitalLPMember 2022-01-01 2022-03-31 0001096938 ueec:CeoAndCmaMember 2022-01-01 2022-03-31 0001096938 ueec:BoardOfDirectorsMember 2021-01-01 2021-01-06 0001096938 ueec:BoardOfDirectorsMember 2022-01-01 2022-03-31 0001096938 ueec:JanuaryOneTwThousandTwentyOneMember 2021-01-01 2021-03-31 0001096938 ueec:RelatedPartyMember 2021-03-31 0001096938 ueec:RelatedPartyMember 2021-01-01 2021-03-31 0001096938 ueec:ConsultantsMember 2021-01-01 2021-03-31 0001096938 ueec:NonAffiliatedInvestorMember us-gaap:PrivatePlacementMember 2021-01-01 2021-03-31 0001096938 ueec:NonAffiliatedInvestorMember us-gaap:PrivatePlacementMember 2022-01-01 2022-03-31 0001096938 ueec:AffiliatedInvestorMember us-gaap:PrivatePlacementMember 2021-01-01 2021-03-31 0001096938 ueec:MrBeplateMember 2021-01-01 2021-03-31 0001096938 ueec:OfficersAndDirectorsMember 2021-01-01 2021-03-31 0001096938 ueec:JanuaryOneTwThousandTwentyOneMember 2022-01-01 2022-03-31 0001096938 ueec:LegalCounselMember 2022-03-31 0001096938 ueec:LegalCounselMember 2022-01-01 2022-03-31 0001096938 ueec:BrianThomMember 2022-03-31 0001096938 ueec:KristoferHeatonMember 2021-12-31 0001096938 ueec:LouisSchiliroMember 2021-12-31 0001096938 ueec:LouisSchiliroMember 2022-03-31 0001096938 ueec:KristoferHeatonMember 2021-01-01 2021-12-31 0001096938 ueec:BrianThomMember 2021-01-01 2021-12-31 0001096938 ueec:LouisSchiliroMember 2021-01-01 2021-12-31 0001096938 ueec:BrianThomMember 2022-01-01 2022-03-31 0001096938 ueec:MrBeplateMember 2022-03-31 0001096938 ueec:KristoferHeatonMember 2022-01-01 2022-03-31 0001096938 ueec:DouglasBeplateMember 2022-01-01 2022-03-31 0001096938 ueec:KristoferHeatonMember 2022-03-31 0001096938 ueec:MrBeplateMember 2021-01-03 2021-01-06 0001096938 ueec:BrianThomMember 2021-12-31 0001096938 ueec:LouisSchiliroMember 2022-01-01 2022-03-31 0001096938 ueec:RestrictedStockUnitsMember 2021-01-01 2021-03-31 0001096938 ueec:RestrictedStockUnitsMember 2022-01-01 2022-03-31 0001096938 ueec:RestrictedStockUnitsMember 2021-03-31 0001096938 us-gaap:RetainedEarningsMember 2022-03-31 0001096938 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001096938 us-gaap:CommonStockMember 2022-03-31 0001096938 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001096938 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001096938 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001096938 us-gaap:RetainedEarningsMember 2021-12-31 0001096938 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001096938 us-gaap:CommonStockMember 2021-12-31 0001096938 2021-03-31 0001096938 us-gaap:RetainedEarningsMember 2021-03-31 0001096938 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001096938 us-gaap:CommonStockMember 2021-03-31 0001096938 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001096938 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001096938 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001096938 2020-12-31 0001096938 us-gaap:RetainedEarningsMember 2020-12-31 0001096938 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001096938 us-gaap:CommonStockMember 2020-12-31 0001096938 2021-01-01 2021-03-31 0001096938 ueec:SeriesAConvertiblePreferredStockMember 2022-03-31 0001096938 ueec:SeriesAConvertiblePreferredStockMember 2021-12-31 0001096938 2021-12-31 0001096938 2022-03-31 0001096938 2022-05-10 iso4217:USD shares iso4217:USD shares pure 0001096938 false --12-31 Q1 2022 0.001 300000000 228667229 228877509 0.001 1000000 0 0 0 100000 100000 0 0 899 45000 0 0 0 45000 37500 2000000 100000 0 0 0 100000 23947300 10-Q true 2022-03-31 false 000-27781 UNITED HEALTH PRODUCTS, INC. NV 84-1517723 10624 S. Eastern Ave., Suite A209 Henderson NV 89052 877 358-3444 Yes Yes Non-accelerated Filer true false false 230127509 32955 21799 5000 5000 37955 26799 39488 0 77443 26799 1014412 826486 138616 3207 450000 120000 85080 0 404000 219000 2092108 1168693 2092108 1168693 0 0 0.001 1000000 0 0 0 0.001 300000000 228877509 228667229 228877 228667 71109164 71017881 -73352706 -72388442 -2014665 -1141894 77443 26799 0 59 0 25 0 34 902146 26647045 52355 58180 954501 26705225 -954501 -26705191 80 221226 8808 389804 -875 -35190 0 304273 -9763 -341947 -964264 -27047138 -0.00 -0.12 228726869 222059641 189357090 189357 40696640 -41839259 -953262 0 234912 0 234912 100000 100 110900 0 111000 125000 125 99875 0 100000 -117647 -117 117 0 0 33930000 33930 26136491 0 26170421 152835 153 161811 0 161964 25000 25 26725 0 26750 1047139 1047 559024 0 560071 1353111 1353 675202 0 676555 0 0 -27047138 -27047138 225972528 225973 68701697 -68886397 41273 228667229 228667 71017881 -72388442 -1141894 20000 20 10180 0 10200 184028 184 77108 0 77292 6252 6 3995 0 4001 0 0 -964264 -964264 228877509 228877 71109164 -73352706 -2014665 964264 27047138 10200 26281421 1012 0 0 604521 -875 -35190 0 -25 0 5000 0 50000 191052 -46312 135409 116805 -430000 0 -195716 -110488 40500 0 -40500 0 185000 20000 14920 0 77292 100000 0 -115000 247372 235000 11156 124512 21799 46076 32955 170588 80 0 0 0 0 117 0 176502 0 676555 0 560071 0 90000 0 26750 0 161964 0 112500 3126 0 100000 0 0 234912 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:justify;"><strong>Note 1. Organization and Basis of Preparation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">United Health Products, Inc. (the “Company”) develops, manufactures, and markets a patented hemostatic gauze for the healthcare and wound care sectors. Our gauze product, HemoStyp®, is a neutralized, oxidized, regenerated cellulose (“NORC”) derived from cotton and designed to absorb exudate/drainage from superficial wounds and help control bleeding. We are in the process of seeking regulatory approval to sell our Hemostyp product line into the U.S. Class III and European Union CE Mark surgical markets.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on April 1, 2022. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In the opinion of management, all adjustments, which are of a normal recurring nature, considered necessary for the fair presentation of financial statements for the interim period, have been included.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:justify;"><strong>Note 2. Significant Accounting Policies</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:justify;"><strong>Going Concern</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred recurring net losses, negative working capital and operations have not provided cash flows. Additionally, the Company does not currently have sufficient revenue producing operations to cover its operating expenses and meet its current obligations. In view of these matters, there is substantial doubt about the Company’s ability to continue as a going concern. The Company intends to finance its future development activities and its working capital needs largely from the sale of equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On March 11, 2020, the World Health Organization declared the outbreak of a coronavirus (COVID-19) as a pandemic. As a result, economic uncertainties have arisen which have the potential to negatively impact the Company’s ability to raise funding and to pursue is business objectives. Other factors that carry financial implications for the Company could occur although the potential impacts are unknown at this time.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Cash and Cash Equivalents</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company considers all highly liquid debt investments purchased with a maturity of three months or less to be cash equivalents.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:justify;"><strong>Use of Estimates</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; TEXT-INDENT: 33.75pt; text-align:justify;">The preparation of financial statements in conformity with generally accepted accounting principles requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reported period. Changes in the economic environment, financial markets, as well as in the healthcare industry, and any other parameters used in determining these estimates, could cause actual results to differ.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> <strong>Revenue Recognition</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company recognizes revenue in accordance with ASC 606, <em>Revenue from Contracts with Customers</em>. Under ASC 606, the Company recognizes revenue from the sale of its HemoStyp product by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company receives orders for its HemoStyp products directly from its customers. Revenues are recognized based on the agreed upon sales or transaction price with the customer when control of the promised goods are transferred to the customer. The transfer of goods to the customer and satisfaction of the Company’s performance obligation will occur either at the time when products are shipped or when the products arrive and are received by the customer. No discounts are currently offered by the Company. The Company does not provide an estimate for returns as there is no anticipation for any returns in the normal course of business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:justify;"><strong>Trade Accounts Receivable and Concentration Risk</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; TEXT-INDENT: 33.75pt; text-align:justify;">We record accounts receivable at the invoiced amount and we do not charge interest. We review the accounts receivable by amounts due from customers that are past due, to identify specific customers with known disputes or collectability issues. In determining the amount of the reserve, we make judgments about the creditworthiness of significant customers based on ongoing credit evaluations. We will also maintain a sales allowance to reserve for potential credits issued to customers. We will determine the amount of the reserve based on historical credit issued.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; TEXT-INDENT: 33.85pt; text-align:justify;">There were no provisions for doubtful accounts recorded at March 31, 2022 and December 31, 2021. The Company recorded $0 and $0 in bad debt expense for the three month periods ended March 31, 2022 and 2021, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:justify;"><strong>Stock Based Compensation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.7pt; TEXT-INDENT: 33.75pt; text-align:justify;">The Company accounts for share-based compensation under the provisions of ASC 718, <em>Compensation-Stock Compensation</em>. Under the fair value recognition provisions, stock-based compensation expense is measured at the fair value of the consideration received, or the fair value of the equity instruments issued, or liabilities incurred, whichever is more reliably measured. Share-based compensation for all stock-based awards to employees and directors is recognized as an expense over the requisite service period, which is generally the vesting period. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.7pt; TEXT-INDENT: 33.75pt; text-align:justify;">The Company accounts for stock compensation arrangements with non-employees in accordance with Accounting Standard Update (ASU) 2018-07, <em>Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting,</em> which requires that such equity instruments are recorded at the value on the grant date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:justify;"><strong>Per Share Information</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Basic earnings per share are calculated using the weighted average number of common shares outstanding for the period presented. Diluted earnings per share is computed using the weighted-average number of common shares and, if dilutive, potential common shares outstanding during the period. The dilutive effect of potential common shares is not reflected in diluted earnings per share because the Company incurred net losses for the three months ended March 31, 2022 and 2021 and the effect of including these potential common shares in the net loss per share calculations would be anti-dilutive. </p>The total potential common shares as of March 31, 2022 included 28,190,000 of restricted stock units. The total potential common shares as of March 31, 2021 includes 27,400,000 of restricted stock units, and 35,294 shares for convertible loans payable - related party. <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Patents</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p>Patents are stated on the balance sheet at cost. Costs, such as filing fees with patent granting agencies and legal fees directly relating to those filings, incurred to file patent applications were capitalized when the Company believed that there was a high likelihood that the patent would be issued and there would be future economic benefit associated with the patent. These costs were amortized from the date of the patent application on a straight-line basis over the estimated useful life of 10 years. All costs associated with any abandoned patent applications are expensed. <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Accumulated amortization as of March 31, 2022 and December 31, 2021 was $1,012 and $0, respectively. Amortization expense for the three months ended March 31, 2022 and 2021 was $1,012 and $0, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">Future Amortization Expense</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Year</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;text-align:right;margin:0px"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2022 (remaining)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,038</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,050</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,050</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,050</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,050</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">20,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">39,488</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Impairment of Long-lived Assets</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The Company applies the provisions of ASC 360, <em>Property, Plant and Equipment,</em> where applicable to all long-lived assets. ASC 360 addresses accounting and reporting for impairment and disposal of long-lived assets. The Company periodically evaluates the carrying value of long-lived assets to be held and used in accordance with ASC 360. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">When long-lived assets are sold or retired, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss is included in the results of operations. During the three months ended March 31, 2022 and 2021, the Company determined no impairment was required.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:justify;"><strong>New Accounting Pronouncements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company considers all new pronouncements and management has determined that there have been no recently adopted or issued accounting standards that had or will have a material impact on its financial statements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred recurring net losses, negative working capital and operations have not provided cash flows. Additionally, the Company does not currently have sufficient revenue producing operations to cover its operating expenses and meet its current obligations. In view of these matters, there is substantial doubt about the Company’s ability to continue as a going concern. The Company intends to finance its future development activities and its working capital needs largely from the sale of equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On March 11, 2020, the World Health Organization declared the outbreak of a coronavirus (COVID-19) as a pandemic. As a result, economic uncertainties have arisen which have the potential to negatively impact the Company’s ability to raise funding and to pursue is business objectives. Other factors that carry financial implications for the Company could occur although the potential impacts are unknown at this time.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company considers all highly liquid debt investments purchased with a maturity of three months or less to be cash equivalents.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; TEXT-INDENT: 33.75pt; text-align:justify;">The preparation of financial statements in conformity with generally accepted accounting principles requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reported period. Changes in the economic environment, financial markets, as well as in the healthcare industry, and any other parameters used in determining these estimates, could cause actual results to differ.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company recognizes revenue in accordance with ASC 606, <em>Revenue from Contracts with Customers</em>. Under ASC 606, the Company recognizes revenue from the sale of its HemoStyp product by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company receives orders for its HemoStyp products directly from its customers. Revenues are recognized based on the agreed upon sales or transaction price with the customer when control of the promised goods are transferred to the customer. The transfer of goods to the customer and satisfaction of the Company’s performance obligation will occur either at the time when products are shipped or when the products arrive and are received by the customer. No discounts are currently offered by the Company. The Company does not provide an estimate for returns as there is no anticipation for any returns in the normal course of business.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; TEXT-INDENT: 33.75pt; text-align:justify;">We record accounts receivable at the invoiced amount and we do not charge interest. We review the accounts receivable by amounts due from customers that are past due, to identify specific customers with known disputes or collectability issues. In determining the amount of the reserve, we make judgments about the creditworthiness of significant customers based on ongoing credit evaluations. We will also maintain a sales allowance to reserve for potential credits issued to customers. We will determine the amount of the reserve based on historical credit issued.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; TEXT-INDENT: 33.85pt; text-align:justify;">There were no provisions for doubtful accounts recorded at March 31, 2022 and December 31, 2021. The Company recorded $0 and $0 in bad debt expense for the three month periods ended March 31, 2022 and 2021, respectively.</p> 0 0 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.7pt; TEXT-INDENT: 33.75pt; text-align:justify;">The Company accounts for share-based compensation under the provisions of ASC 718, <em>Compensation-Stock Compensation</em>. Under the fair value recognition provisions, stock-based compensation expense is measured at the fair value of the consideration received, or the fair value of the equity instruments issued, or liabilities incurred, whichever is more reliably measured. Share-based compensation for all stock-based awards to employees and directors is recognized as an expense over the requisite service period, which is generally the vesting period. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.7pt; TEXT-INDENT: 33.75pt; text-align:justify;">The Company accounts for stock compensation arrangements with non-employees in accordance with Accounting Standard Update (ASU) 2018-07, <em>Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting,</em> which requires that such equity instruments are recorded at the value on the grant date.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Basic earnings per share are calculated using the weighted average number of common shares outstanding for the period presented. Diluted earnings per share is computed using the weighted-average number of common shares and, if dilutive, potential common shares outstanding during the period. The dilutive effect of potential common shares is not reflected in diluted earnings per share because the Company incurred net losses for the three months ended March 31, 2022 and 2021 and the effect of including these potential common shares in the net loss per share calculations would be anti-dilutive. </p>The total potential common shares as of March 31, 2022 included 28,190,000 of restricted stock units. The total potential common shares as of March 31, 2021 includes 27,400,000 of restricted stock units, and 35,294 shares for convertible loans payable - related party. 28190000 27400000 35294 Patents are stated on the balance sheet at cost. Costs, such as filing fees with patent granting agencies and legal fees directly relating to those filings, incurred to file patent applications were capitalized when the Company believed that there was a high likelihood that the patent would be issued and there would be future economic benefit associated with the patent. These costs were amortized from the date of the patent application on a straight-line basis over the estimated useful life of 10 years. All costs associated with any abandoned patent applications are expensed. <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Accumulated amortization as of March 31, 2022 and December 31, 2021 was $1,012 and $0, respectively. Amortization expense for the three months ended March 31, 2022 and 2021 was $1,012 and $0, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">Future Amortization Expense</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Year</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;text-align:right;margin:0px"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2022 (remaining)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,038</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,050</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,050</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,050</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,050</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">20,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">39,488</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> straight-line basis over the estimated useful life of 10 years 1012 0 1012 0 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Year</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;text-align:right;margin:0px"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2022 (remaining)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,038</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,050</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,050</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,050</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,050</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">20,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">39,488</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 3038 4050 4050 4050 4050 20250 39488 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The Company applies the provisions of ASC 360, <em>Property, Plant and Equipment,</em> where applicable to all long-lived assets. ASC 360 addresses accounting and reporting for impairment and disposal of long-lived assets. The Company periodically evaluates the carrying value of long-lived assets to be held and used in accordance with ASC 360. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">When long-lived assets are sold or retired, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss is included in the results of operations. During the three months ended March 31, 2022 and 2021, the Company determined no impairment was required.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company considers all new pronouncements and management has determined that there have been no recently adopted or issued accounting standards that had or will have a material impact on its financial statements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:justify;"><strong>Note 3. Related Party Transactions</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:justify;"><em>Loans payable - related parties</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; TEXT-INDENT: 33.75pt; text-align:justify;">As of December 31, 2021, 21, Brian Thom, Chief Executive Officer had a loan payable balance of $175,000.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; TEXT-INDENT: 33.75pt; text-align:justify;">During the three months ended March 31, 2022, Mr. Thom loaned the Company $165,000 to pay for operating expenses. As of March 31, 2022, $340,000 is owed to Mr. Thom. The loans have an interest rate of 10% and have a maturity date of December 31, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; TEXT-INDENT: 33.75pt; text-align:justify;">As of December 31, 2021, Lou Schiliro, the former Chief Operating Officer, had a loan payable balance of $44,000. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; TEXT-INDENT: 33.75pt; text-align:justify;">During the three months ended March 31, 2022, Mr. Schiliro, loaned the Company $20,000 to pay for operating expenses. As of March 31, 2022, $64,000 is owed to Mr. Schiliro. The loans have an interest rate of 10% and have a maturity date of December 31, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Interest expense – related party on the above loans was $8,808 during the three months ended March 31, 2022. Accrued interest – related party as of March 31, 2022 and December 31, 2021 was $11,116 and $2,308, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Accrued liabilities – related parties</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">As of March 31, 2022 and December 31, 2021, $45,000 and $899 was owed to Mr. Thom for accrued compensation and reimbursable expenses, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">As of March 31, 2022 and December 31, 2021, $45,000 and $0 was owed to Mr. Schiliro for accrued compensation, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">As of March 31, 2022 and December 31, 2021, $37,500 and $0 was owed to Kristofer Heaton, the Principal Financial Officer, for accrued compensation, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Equity transactions</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Per the vesting schedules of certain of the Company’s amended RSU Agreements, on January 1, 2021, 6,760,000 shares of common stock were issued to Mr. Douglas Beplate, former Chairman of the Board, 2,000,000 shares of common stock were issued to Mr. Schiliro and 100,000 shares of common stock were issued to Mr. Heaton.</p>On January 6, 2021, the Board of Directors approved the second amendment to the RSU Agreement between the Company and Mr. Beplate in conjunction with Mr. Beplate’s retirement from his day-to-day management role with the Company. The amendment accelerated the vesting and immediately settled his remaining RSUs by issuing 21,970,000 shares of common stock. Further, as a bonus in recognition of Mr. Beplate’s service to the Company and in recruitment of new executive management, the Company issued to Mr. Beplate an additional 2,000,000 shares of common stock. The Company recorded $26,127,300 of stock-based compensation expense during the three months ended March 31, 2021 related to the accelerated vesting of these RSU’s and issuance of common stock. 175000 165000 340000 0.10 2022-12-31 44000 20000 64000 0.10 2022-12-31 8808 11116 2308 45000 899 45000 37500 0 6760000 2000000 100000 21970000 2000000 26127300 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Note 4. Promissory Note Payable</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">During the three months ended March 31, 2022, the Company reached a settlement agreement related to Patterson’s counterclaim (see Note 6). The Company agreed to pay $120,000 which had previously been accrued as of December 31, 2021. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The Company paid $20,000 of the settlement and entered into a $100,000 promissory note with its legal counsel to fund the payment of the remaining balance. The Company paid $14,920 of principal and $80 in interest expense leaving a principal balance of $85,080 and accrued interest of $0 as of March 31, 2022. The note accrues interest at 1% and requires monthly payments of $9,136 until the balance is paid in full. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The promissory note is secured by 200,000 shares of restricted common stock which would have demand registration rights and the Company would file a registration statement within 45 days of the request.</p> 120000 2021-12-31 20000 14920 80 85080 0 0.01 9136 200000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Note 5. Issuances of Securities</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline">Share issuances 2021</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; TEXT-INDENT: 33.75pt; text-align:justify;">During the three months ended March 31, 2021, a total of 31,930,000 shares of common stock were issued to officers, directors and various consultants related to vesting of RSU’s with a total stock-based compensation cost of $23,990,421, 2,000,000 shares of common stock were issued to Mr. Beplate as a stock bonus with a stock-based compensation cost of $2,180,000, 125,000 shares of common stock were sold to an affiliated investor in a private placement for total cash proceeds of $100,000, 100,000 shares of common stock were issued for settlement of a business consulting agreement with a fair value of $111,000, 25,000 shares of commons stock were issued to settle $20,000 of related party advances, 152,835 shares of common stock were issued to settle $133,523 of accrued liabilities – related party, 1,047,139 shares of common stock were issued due to the conversion of convertible notes payable and accrued interest, 1,353,111 shares of common stock were issued due to the conversion of convertible notes payable and accrued interest – related party and 117,647 shares of common stock were cancelled.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline">Share issuances 2022</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; TEXT-INDENT: 33.75pt; text-align:justify;">During the three months ended March 31, 2022, 184,028 shares of common stock were sold to non-affiliated investors in a private placement for total cash proceeds of $77,292, 6,252 shares of commons stock were issued to settle $3,126 of accrued liabilities resulting in a loss on settlement of debt of $875 and 20,000 shares of common stock with a fair value of $10,200 were issued for legal services.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline">Restricted stock units</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">As discussed in Note 3, during the year ended December 31, 2020 the Board of Directors approved amendments to its March 25, 2019 RSU Agreement for certain management and consultants to the Company. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The amendment resulted in 9,960,000 of the RSU’s vesting on January 1, 2021. The fair value of the 9,960,000 RSU’s. The compensation expense was being amortized on a straight-line basis from the date of the amendment through January 1, 2021 which is the vesting date. Stock-based compensation of $43,121 was recognized as expense during the three months ended March 31, 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On January 6, 2021, the Board of Directors approved the second amendment to the Restricted Stock Unit Agreement between the Company and Mr. Beplate, former Chief Executive Officer and former Chairman of the Board, in conjunction with Mr. Beplate’s retirement from his day-to-day management role with the Company. The amendment accelerated the vesting and immediately settled his remaining RSUs by issuing 21,970,000 shares of common stock. </p>Per ASC 718-20-35, the change in vesting conditions resulted in a modification of the stock-based compensation awards. The modification is considered a Type III modification as described in ASC 718-20-55 and resulted in recording $23,947,300 of stock-based compensation expense which was the fair value of the shares on the date of the modification. <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Activity related to our restricted stock units during the three months ended March 31, 2022 was as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Weighted </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Average</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Grant </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Number of </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Date Fair </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Units </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Value </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total awards outstanding at December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,190,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.96</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Units granted </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Units Exercised/Released </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Units Cancelled/Forfeited </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total awards outstanding at March 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">28,190,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.96</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; TEXT-INDENT: 33.75pt; text-align:justify;">Management is unable to predict if or when a Covered Transaction or Triggering Event under the RSU Agreements governing the restricted stock units will occur and as of March 31, 2022, there was $27,017,200 of unrecognized compensation cost related to unvested restricted stock unit awards.  </p> 31930000 23990421 2000000 2180000 125000 100000 100000 111000 25000 20000 152835 133523 1047139 1353111 117647 184028 77292 6252 3126 875 20000 10200 9960000 43121 21970000 23947300 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Weighted </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Average</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Grant </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Number of </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Date Fair </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Units </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Value </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total awards outstanding at December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,190,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.96</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Units granted </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Units Exercised/Released </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Units Cancelled/Forfeited </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total awards outstanding at March 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">28,190,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.96</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 28190000 0.96 0 0 0 28190000 0.96 27017200 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:justify;"><strong>Note 6. Litigation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Philip Forman, who served as Chairman, a director, Chief Executive Officer and Chief Medical Advisor of the Company at various times between 2011 and October 2015, filed a lawsuit against the Company and our then-Chief Executive Officer, Douglas Beplate, in the United States District Court of the District of Nevada. The plaintiff has claimed, among other things: that the June 25, 2015 Amendment to his November 10, 2014 Employment Agreement with the Company, which terminated the Employment Agreement on October 1, 2015, is not enforceable due to lack of consideration; that a July 22, 2015 Stock Purchase Agreement pursuant to which the plaintiff sold Company shares issued to him under the Amendment to a third a party is unenforceable (despite the fact that all payment for the shares under the Stock Purchase Agreement was made); that the plaintiff’s 2014 Employment Agreement remains valid and that he is entitled to cash and stock compensation under that Employment Agreement (without giving regard to the Amendment); and that the Company and Mr. Beplate defrauded the plaintiff relating to the foregoing. The plaintiff is seeking declaratory judgment regarding the parties’ relative rights under the Employment Agreement, the Amendment and the Stock Purchase Agreement; money damages of no less than $2,795,000; and punitive damages of $8,280,000. The Company filed a motion to dismiss the plaintiff’s claims which was denied on March 19, 2020. On May 5, 2021, the plaintiff provided a deposition as instructed by the Court, subsequent to which the Company filed a motion for dismissal of this proceeding<em>. </em>On February 14, 2022, the Court issued an Order which declared the Amendment to be unenforceable and thus the terms of the original Employment Agreement to remain in effect. The Order also noted that the Company is not a party to the Stock Purchase Agreement, and the Employment Agreement does not constitute a prior agreement that could have been superseded by the Stock Purchase Agreement. The parties are currently engaged in settlement discussions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In 2018 an action was commenced in the United States District Court Southern District of New York entitled JEC Consulting Associates, LLC. Liquidator of Lead Dog Capital LP against United Health Products t/k/a United EcoEnergy Corp and Douglas K. Beplate under Docket Number 18-cv-1139 (ER). The third-party action sought to remove a restrictive legend from a particular stock certificate for Three Million Fifty Thousand (3,050,000) shares and declare the shares to be free trading. The third-party plaintiff alleges that the Company and Mr. Beplate refused to have the restrictive legend on the stock certificate removed under Rule 144 and sought compensatory and punitive damages. The Federal court issued an order that the Securities Exchange Commission should review the claim before the District Court renders a final ruling. Discovery appears to be substantially complete and settlement discussions between the third-party plaintiff and the Company have been initiated. On April 22, 2022 the parties entered in a Settlement Agreement wherein the Company would agree to allow the removal of the restrictive legend as permitted under applicable securities laws and distribution of the shares to affiliates of the plaintiffs. Under the Settlement Agreement the Company will make no payments other than to pay expenses related to its own legal counsel. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Due to uncertainties inherent in litigation, we cannot predict the outcome of the above legal proceedings.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company has commenced the following legal proceedings:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 34.1pt; text-align:justify;">On February 7, 2020, the Company filed the Original Petition for Fraud and Breach of Contract in the Texas District Court for the 215th Judicial District of Harris County against defendants Patterson Companies Inc., Patterson Management, L.P., Patterson Veterinary, Inc. and Patterson Logistics Services, Inc., and Animal Health International, Inc. On March 5, 2020, the defendants removed the case to U.S. District Court for Southern District of Texas. The defendants filed their answer in federal court on March 12, 2020. The original August 25, 2020 pretrial deadlines were extended. On January 18, 2022, the Company’s claims were dismissed, with prejudice, by the court. On February 9, 2022, the Company and Patterson reached an agreement on settlement of Patterson’s counterclaim. The Company agreed to pay $120,000 which was accrued as of December 31, 2021. The $120,000 settlement payment was paid in full in February 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In August 2020, United Health Products filed suit against its former auditors, Haynie &amp; Company, in Utah State Court, asserting claims related to professional negligence and breach of fiduciary duty. Haynie &amp; Company has denied the allegations. Discovery is largely complete and the parties have each submitted a report by their respective expert witness to the Court.</p> 2795000 8280000 in the United States District Court Southern District of New York entitled JEC Consulting Associates, LLC. Liquidator of Lead Dog Capital LP against United Health Products t/k/a United EcoEnergy Corp and Douglas K. Beplate under Docket Number 18-cv-1139 (ER). The third-party action sought to remove a restrictive legend from a particular stock certificate for Three Million Fifty Thousand (3,050,000) shares and declare the shares to be free trading 120000 120000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:justify;"><strong>Note 7. Other Income</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company received payment of $304,273 from Maxim Group LLC, as full and final settlement of its previously disclosed arbitration between the Company and Maxim that was settled in December 2019. The $304,273 was recorded as other income in the Statement of Operations during the three months ended March 31, 2021. </p> 304273 304273 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:justify;"><strong>Note 8. Subsequent Events </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company has evaluated events from March 31, 2022, through the date whereupon the financial statements were issued and has determined that there are no material events that need to be disclosed except as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In connection with the Securities and Exchange Commission’s investigation against the Company, Douglas Beplate, the former Chief Executive Officer and Chairman and a former director of the Company, and Louis Schiliro, the former Chief Operating Officer and a former director of the Company, concerning possible violations of certain provisions of the Securities Act of 1933 and the Securities Exchange Act of 1934, the Commission’s Enforcement Division has presented proposed settlement terms which the Enforcement Division has indicated it would recommend to the Commission to resolve the matter as to the Company, if acceptable to the Company. The investigation was previously reported by the Company in its prior periodic reports including its Annual Report for the year ended December 31, 2021 under Item 1A “Risk Factors”.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The proposed resolution terms of the investigation presented by the Commission would include a consent judgment against the Company on the following terms, among others, without the Company admitting or denying the Commission’s allegations:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">The Company being permanently enjoined from violating: Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 under the Exchange Act; Section 17(a) of the Securities Act of 1933; Section 13(a) of the Exchange Act and Rules 12b-20, 13a-1 and 13a-13 under the Exchange Act; Section 13(b)(2)(A) of the Exchange Act; and Section 13(b)(2)(B) of the Exchange Act.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px;text-indent:30px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">The Company being required to pay a civil penalty of $450,000, payable in four installments as follows: $50,000 upon the entry of the judgment; $100,000 within 90 days of the entry of the judgment; $150,000 within 180 days of the entry of the judgment; and $150,000 within 270 days of the entry of the judgment, plus statutory interest on payments made after 30 days of the entry of the judgment pursuant to U.S.C. Section 1961.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Additionally, the Company’s consent would include the Company’s agreement not to take any action or make any public statement denying any allegations in the Commission’s complaint or creating the impression that the complaint is without factual basis; and not to make any public statement to the effect that the Company does not admit the allegations in the complaint without also stating that the Company does not deny the allegations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The $450,000 civil penalty has been accrued as of March 31, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The Company received a total of $50,000 in advances from its Chief Executive Officer.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The Company issued a total of 1,250,000 shares of common stock to officers and various consultants for accrued compensation and services provided in lieu of cash salary payments due under their respective consulting agreements.</p> The Company being required to pay a civil penalty of $450,000, payable in four installments as follows: $50,000 upon the entry of the judgment; $100,000 within 90 days of the entry of the judgment; $150,000 within 180 days of the entry of the judgment; and $150,000 within 270 days of the entry of the judgment, plus statutory interest on payments made after 30 days 450000 50000 1250000 EXCEL 38 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 39 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 40 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 41 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 65 206 1 false 25 0 false 4 false false R1.htm 000001 - Document - Cover Sheet http://unitedhealthproductsinc.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - Condensed Balance Sheets Sheet http://unitedhealthproductsinc.com/role/CondensedBalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 000003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 000005 - Statement - Condensed Statement of Stockholders Equity (Unaudited) Sheet http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited Condensed Statement of Stockholders Equity (Unaudited) Statements 5 false false R6.htm 000006 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited Condensed Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 000007 - Disclosure - Organization and Basis of Preparation Sheet http://unitedhealthproductsinc.com/role/OrganizationAndBasisOfPreparation Organization and Basis of Preparation Notes 7 false false R8.htm 000008 - Disclosure - Significant Accounting Policies Sheet http://unitedhealthproductsinc.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 000009 - Disclosure - Related Party Transactions Sheet http://unitedhealthproductsinc.com/role/RelatedPartyTransactions Related Party Transactions Notes 9 false false R10.htm 000010 - Disclosure - Promissory Note Payable Sheet http://unitedhealthproductsinc.com/role/PromissoryNotePayable Promissory Note Payable Notes 10 false false R11.htm 000011 - Disclosure - Issuances of Securities Sheet http://unitedhealthproductsinc.com/role/IssuancesOfSecurities Issuances of Securities Notes 11 false false R12.htm 000012 - Disclosure - Litigation Sheet http://unitedhealthproductsinc.com/role/Litigation Litigation Notes 12 false false R13.htm 000013 - Disclosure - Other Income Sheet http://unitedhealthproductsinc.com/role/OtherIncome Other Income Notes 13 false false R14.htm 000014 - Disclosure - Subsequent Event Sheet http://unitedhealthproductsinc.com/role/SubsequentEvent Subsequent Event Notes 14 false false R15.htm 000015 - Disclosure - Significant Accounting Policies (Policies) Sheet http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://unitedhealthproductsinc.com/role/SignificantAccountingPolicies 15 false false R16.htm 000016 - Disclosure - Significant Accounting Policies (Tables) Sheet http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://unitedhealthproductsinc.com/role/SignificantAccountingPolicies 16 false false R17.htm 000017 - Disclosure - Issuances of Securities (Tables) Sheet http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesTables Issuances of Securities (Tables) Tables http://unitedhealthproductsinc.com/role/IssuancesOfSecurities 17 false false R18.htm 000018 - Disclosure - Significant Accounting Policies (Details) Sheet http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Details http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesTables 18 false false R19.htm 000019 - Disclosure - Significant Accounting Policies (Details Narrative) Sheet http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative Significant Accounting Policies (Details Narrative) Details http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesTables 19 false false R20.htm 000020 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://unitedhealthproductsinc.com/role/RelatedPartyTransactions 20 false false R21.htm 000021 - Disclosure - Promissory Note Payable (Details Narrative) Sheet http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative Promissory Note Payable (Details Narrative) Details http://unitedhealthproductsinc.com/role/PromissoryNotePayable 21 false false R22.htm 000022 - Disclosure - Issuances of Securities (Details) Sheet http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetails Issuances of Securities (Details) Details http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesTables 22 false false R23.htm 000023 - Disclosure - Issuances of Securities (Details Narrative) Sheet http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative Issuances of Securities (Details Narrative) Details http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesTables 23 false false R24.htm 000024 - Disclosure - Litigation (Details Narrative) Sheet http://unitedhealthproductsinc.com/role/LitigationDetailsNarrative Litigation (Details Narrative) Details http://unitedhealthproductsinc.com/role/Litigation 24 false false R25.htm 000025 - Disclosure - Other Income (Details Narrative) Sheet http://unitedhealthproductsinc.com/role/OtherIncomeDetailsNarrative Other Income (Details Narrative) Details http://unitedhealthproductsinc.com/role/OtherIncome 25 false false R26.htm 000026 - Disclosure - Subsequent Events (Details Narrative) Sheet http://unitedhealthproductsinc.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://unitedhealthproductsinc.com/role/SubsequentEvent 26 false false All Reports Book All Reports ueec_10q.htm ueec-20220331.xsd ueec-20220331_cal.xml ueec-20220331_def.xml ueec-20220331_lab.xml ueec-20220331_pre.xml ueec_ex311.htm ueec_ex312.htm ueec_ex321.htm ueec_ex322.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 44 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ueec_10q.htm": { "axisCustom": 0, "axisStandard": 8, "contextCount": 65, "dts": { "calculationLink": { "local": [ "ueec-20220331_cal.xml" ] }, "definitionLink": { "local": [ "ueec-20220331_def.xml" ] }, "inline": { "local": [ "ueec_10q.htm" ] }, "labelLink": { "local": [ "ueec-20220331_lab.xml" ] }, "presentationLink": { "local": [ "ueec-20220331_pre.xml" ] }, "schema": { "local": [ "ueec-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 277, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 19, "http://unitedhealthproductsinc.com/20220331": 8, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 32 }, "keyCustom": 67, "keyStandard": 139, "memberCustom": 21, "memberStandard": 4, "nsprefix": "ueec", "nsuri": "http://unitedhealthproductsinc.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "role": "http://unitedhealthproductsinc.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "ueec:PromissoryNotePayabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - Promissory Note Payable", "role": "http://unitedhealthproductsinc.com/role/PromissoryNotePayable", "shortName": "Promissory Note Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "ueec:PromissoryNotePayabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "ueec:IssuancesOfSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - Issuances of Securities", "role": "http://unitedhealthproductsinc.com/role/IssuancesOfSecurities", "shortName": "Issuances of Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "ueec:IssuancesOfSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - Litigation", "role": "http://unitedhealthproductsinc.com/role/Litigation", "shortName": "Litigation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - Other Income", "role": "http://unitedhealthproductsinc.com/role/OtherIncome", "shortName": "Other Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - Subsequent Event", "role": "http://unitedhealthproductsinc.com/role/SubsequentEvent", "shortName": "Subsequent Event", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "ueec:PatentsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAmortizationExpensePerUnitOfProductionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - Significant Accounting Policies (Tables)", "role": "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ueec:PatentsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAmortizationExpensePerUnitOfProductionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - Issuances of Securities (Tables)", "role": "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesTables", "shortName": "Issuances of Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAmortizationExpensePerUnitOfProductionTextBlock", "ueec:PatentsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - Significant Accounting Policies (Details)", "role": "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetails", "shortName": "Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAmortizationExpensePerUnitOfProductionTextBlock", "ueec:PatentsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "p", "ueec:PatentsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "ueec:AccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - Significant Accounting Policies (Details Narrative)", "role": "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative", "shortName": "Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ueec:PatentsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "ueec:AccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - Condensed Balance Sheets", "role": "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets", "shortName": "Condensed Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromRelatedPartyDebt", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - Related Party Transactions (Details Narrative)", "role": "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31_ueec_KristoferHeatonMember", "decimals": "0", "lang": null, "name": "us-gaap:CostsAndExpenses", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "p", "ueec:PromissoryNotePayabletextblock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - Promissory Note Payable (Details Narrative)", "role": "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative", "shortName": "Promissory Note Payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ueec:PromissoryNotePayabletextblock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31_ueec_LegalCounselMember", "decimals": "0", "lang": null, "name": "us-gaap:RepaymentsOfDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "ueec:NumberOfUnitsTotalAwardsOutstandingBeginning", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - Issuances of Securities (Details)", "role": "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetails", "shortName": "Issuances of Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "ueec:NumberOfUnitsTotalAwardsOutstandingBeginning", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "ueec:IssuancesOfSecuritiesTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetSale", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - Issuances of Securities (Details Narrative)", "role": "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative", "shortName": "Issuances of Securities (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ueec:IssuancesOfSecuritiesTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetSale", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "ueec:PromissoryNotePayabletextblock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - Litigation (Details Narrative)", "role": "http://unitedhealthproductsinc.com/role/LitigationDetailsNarrative", "shortName": "Litigation (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "lang": null, "name": "ueec:LitigationSettlementSharesIssuableUnderAgreementFairValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherIncome", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - Other Income (Details Narrative)", "role": "http://unitedhealthproductsinc.com/role/OtherIncomeDetailsNarrative", "shortName": "Other Income (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31_ueec_MaximGroupLLCMember", "decimals": "0", "lang": null, "name": "us-gaap:OtherIncome", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "ueec:DescriptionOfInstallment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - Subsequent Events (Details Narrative)", "role": "http://unitedhealthproductsinc.com/role/SubsequentEventsDetailsNarrative", "shortName": "Subsequent Events (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "ueec:DescriptionOfInstallment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - Condensed Balance Sheets (Parenthetical)", "role": "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical", "shortName": "Condensed Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - Condensed Statements of Operations (Unaudited)", "role": "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited", "shortName": "Condensed Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - Condensed Statement of Stockholders Equity (Unaudited)", "role": "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited", "shortName": "Condensed Statement of Stockholders Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - Condensed Statements of Cash Flows (Unaudited)", "role": "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000007 - Disclosure - Organization and Basis of Preparation", "role": "http://unitedhealthproductsinc.com/role/OrganizationAndBasisOfPreparation", "shortName": "Organization and Basis of Preparation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - Significant Accounting Policies", "role": "http://unitedhealthproductsinc.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - Related Party Transactions", "role": "http://unitedhealthproductsinc.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 25, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r123", "r219" ], "lang": { "en-us": { "role": { "label": "Title Of Individual Axis" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/LitigationDetailsNarrative", "http://unitedhealthproductsinc.com/role/OtherIncomeDetailsNarrative", "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/LitigationDetailsNarrative", "http://unitedhealthproductsinc.com/role/OtherIncomeDetailsNarrative", "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_AccruedLitigationSettlementPaidWithLoanPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued litigation settlement paid with loan payable" } } }, "localname": "AccruedLitigationSettlementPaidWithLoanPayable", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_AccruedLitigationSettlements": { "auth_ref": [], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.", "label": "Accrued litigation settlement" } } }, "localname": "AccruedLitigationSettlements", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ueec_AccumulatedAmortization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accumulated amortization" } } }, "localname": "AccumulatedAmortization", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_AdditionalRsuSIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Additional RSU's issued" } } }, "localname": "AdditionalRsuSIssued", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ueec_AffiliatedInvestorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Affiliated Investor [Member]" } } }, "localname": "AffiliatedInvestorMember", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_AmountOwed": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Amount owed" } } }, "localname": "AmountOwed", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_BoardOfDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Board of Directors [Member]" } } }, "localname": "BoardOfDirectorsMember", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_BrianThomMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Brian Thom [Member]" } } }, "localname": "BrianThomMember", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_CEOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CEO [Member]" } } }, "localname": "CEOMember", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_CancellationOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Cancellation of common stock" } } }, "localname": "CancellationOfCommonStock", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_CancellationOfCommonStockAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Cancellation of common stock, amount" } } }, "localname": "CancellationOfCommonStockAmount", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_CancellationOfCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cancellation of common stock, shares" } } }, "localname": "CancellationOfCommonStockShares", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ueec_CashProceeds": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Cash proceeds" } } }, "localname": "CashProceeds", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_CeoAndCmaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Former Chief Executive Officer and Chief Medical Advisor [Member]" } } }, "localname": "CeoAndCmaMember", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/LitigationDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_CommonStockFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock, fair value" } } }, "localname": "CommonStockFairValue", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_CommonStockIssuedForConversionOfConvertibleNotesPayableAndAccruedInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Common stock issued for conversion of convertible notes payable and accrued interest" } } }, "localname": "CommonStockIssuedForConversionOfConvertibleNotesPayableAndAccruedInterest", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_CommonStockIssuedForConversionOfConvertibleNotesPayableAndAccruedInterestRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Common stock issued for conversion of convertible notes payable and accrued interest - related party" } } }, "localname": "CommonStockIssuedForConversionOfConvertibleNotesPayableAndAccruedInterestRelatedParty", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_CommonStockIssuedForConversionOfConvertibleNotesPayableAndAccruedInterestRelatedPartyAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued for conversion of convertible notes payable and accrued interest - related party, amount" } } }, "localname": "CommonStockIssuedForConversionOfConvertibleNotesPayableAndAccruedInterestRelatedPartyAmount", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_CommonStockIssuedForConversionOfConvertibleNotesPayableAndAccruedInterestRelatedPartyShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued for conversion of convertible notes payable and accrued interest - related party, shares" } } }, "localname": "CommonStockIssuedForConversionOfConvertibleNotesPayableAndAccruedInterestRelatedPartyShares", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ueec_CommonStockIssuedToSettleAccountsPayableAndAccruedLiabilitiesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued to settle accounts payable and accrued liabilities, amount" } } }, "localname": "CommonStockIssuedToSettleAccountsPayableAndAccruedLiabilitiesAmount", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_CommonStockIssuedToSettleAccountsPayableAndAccruedLiabilitiesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued to settle accounts payable and accrued liabilities, shares" } } }, "localname": "CommonStockIssuedToSettleAccountsPayableAndAccruedLiabilitiesShares", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ueec_CommonStockIssuedToSettleAccruedLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued to settle accrued liabilities" } } }, "localname": "CommonStockIssuedToSettleAccruedLiabilities", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_CommonStockIssuedToSettleAccruedLiabilitiesRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued to settle accrued liabilities - related party" } } }, "localname": "CommonStockIssuedToSettleAccruedLiabilitiesRelatedParty", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_CommonStockIssuedToSettleAccruedLiabilitiesRelatedPartyAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued to settle accrued liabilities - related party, amount" } } }, "localname": "CommonStockIssuedToSettleAccruedLiabilitiesRelatedPartyAmount", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_CommonStockIssuedToSettleAccruedLiabilitiesRelatedPartyShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued to settle accrued liabilities - related party, shares" } } }, "localname": "CommonStockIssuedToSettleAccruedLiabilitiesRelatedPartyShares", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ueec_CommonStockIssuedToSettleRelatedPartyAdvances": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that por", "label": "Common stock issued to settle related party advances" } } }, "localname": "CommonStockIssuedToSettleRelatedPartyAdvances", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_CommonStockIssuedToSettleRelatedPartyAdvancesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued to settle related party advances, amount" } } }, "localname": "CommonStockIssuedToSettleRelatedPartyAdvancesAmount", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_CommonStockIssuedToSettleRelatedPartyAdvancesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued to settle related party advances, shares" } } }, "localname": "CommonStockIssuedToSettleRelatedPartyAdvancesShares", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ueec_CommonStockShareIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock share issued" } } }, "localname": "CommonStockShareIssued", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ueec_CommonStockSharesCancellations": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock shares cancellations" } } }, "localname": "CommonStockSharesCancellations", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ueec_ConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consultants [Member]" } } }, "localname": "ConsultantsMember", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_ConversionOfAccountsPayableToConvertibleNotesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of accounts payable to convertible notes payable" } } }, "localname": "ConversionOfAccountsPayableToConvertibleNotesPayable", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_ConversionOfAccruedLiabilitiesRelatedPartyToConvertibleNotesPayableRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of accrued liabilities - related party to convertible notes payable - related party" } } }, "localname": "ConversionOfAccruedLiabilitiesRelatedPartyToConvertibleNotesPayableRelatedParty", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_ConversionOfConvertibleNotesPayableAndAccruedInterestRelatedPartyToConvertibleNotesPayableAndAccruedInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of convertible notes payable and accrued interest - related party to convertible notes payable and accrued interest" } } }, "localname": "ConversionOfConvertibleNotesPayableAndAccruedInterestRelatedPartyToConvertibleNotesPayableAndAccruedInterest", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_ConvertibleLoansPayableSharesRelatedParty": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible loans Payable shares, related party" } } }, "localname": "ConvertibleLoansPayableSharesRelatedParty", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ueec_DebtDiscountRelatedToBeneficialConversionFeature": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Debt discount related to beneficial conversion feature" } } }, "localname": "DebtDiscountRelatedToBeneficialConversionFeature", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_DescriptionOfInstallment": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of installment" } } }, "localname": "DescriptionOfInstallment", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "ueec_DescriptionOfPatent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of patent" } } }, "localname": "DescriptionOfPatent", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "ueec_DouglasBeplateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Douglas Beplate [Member]" } } }, "localname": "DouglasBeplateMember", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_EarningPerShareBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and diluted" } } }, "localname": "EarningPerShareBasicAndDiluted", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "ueec_FiniteLivedIntangibleAssetsAmortizationExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Future Amortization Expense" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpense", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "ueec_FormerOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Former Officer [Member]" } } }, "localname": "FormerOfficerMember", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_IncreaseDecreaseInAccruedLitigationSettlement": { "auth_ref": [], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Accrued litigation settlement]", "negatedLabel": "Accrued litigation settlement" } } }, "localname": "IncreaseDecreaseInAccruedLitigationSettlement", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_IncreasedecreaseinsubscriptionReceivable": { "auth_ref": [], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Subscription Receivable]", "negatedLabel": "Subscription Receivable" } } }, "localname": "IncreasedecreaseinsubscriptionReceivable", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_IssuanceOfCommonStockForServicesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of common stock for services, amount" } } }, "localname": "IssuanceOfCommonStockForServicesAmount", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_IssuanceOfCommonStockForServicesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock for services, shares" } } }, "localname": "IssuanceOfCommonStockForServicesShares", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ueec_IssuancesOfSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Issuances of Securities]", "verboseLabel": "Issuances of Securities" } } }, "localname": "IssuancesOfSecuritiesTextBlock", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecurities" ], "xbrltype": "textBlockItemType" }, "ueec_JanuaryOneTwThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "January 1, 2021 [Member]" } } }, "localname": "JanuaryOneTwThousandTwentyOneMember", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_KristoferHeatonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Kristofer Heaton [Member]" } } }, "localname": "KristoferHeatonMember", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_LeadDogCapitalLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lead Dog Capital LP [Member]" } } }, "localname": "LeadDogCapitalLPMember", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/LitigationDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_LegalCounselMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Legal Counsel [Member]" } } }, "localname": "LegalCounselMember", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_LitigationSettlementSharesIssuableUnderAgreementFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Litigation settlement, shares issuable under agreement, fair value" } } }, "localname": "LitigationSettlementSharesIssuableUnderAgreementFairValue", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/LitigationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_LossContingencyDamagesSoughtPunitiveDamages": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Loss contingency damages sought, punitive damages" } } }, "localname": "LossContingencyDamagesSoughtPunitiveDamages", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/LitigationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_LouisSchiliroMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Louis Schiliro [Member]" } } }, "localname": "LouisSchiliroMember", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_MarchTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "March 2021 [Member]" } } }, "localname": "MarchTwoThousandTwentyOneMember", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/OtherIncomeDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_MaximGroupLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Maxim Group LLC [Member]" } } }, "localname": "MaximGroupLLCMember", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/OtherIncomeDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_MrBeplateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mr. Beplate [Member]" } } }, "localname": "MrBeplateMember", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_NonAffiliatedInvestorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non Affiliated Investor [Member]" } } }, "localname": "NonAffiliatedInvestorMember", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_NotePayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Promissory note" } } }, "localname": "NotePayable", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_NumberOfUnitsCancelledForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of units cancelled/forfeited" } } }, "localname": "NumberOfUnitsCancelledForfeited", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "ueec_NumberOfUnitsExercisedReleased": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of units exercised/released" } } }, "localname": "NumberOfUnitsExercisedReleased", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "ueec_NumberOfUnitsTotalAwardsOutstandingBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of units total awards outstanding, beginning" } } }, "localname": "NumberOfUnitsTotalAwardsOutstandingBeginning", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "ueec_NumberOfUnitsTotalAwardsOutstandingEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of units total awards outstanding, ending" } } }, "localname": "NumberOfUnitsTotalAwardsOutstandingEnding", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "ueec_OfficersAndDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Officers And Directors [Member]" } } }, "localname": "OfficersAndDirectorsMember", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_PatentsNet": { "auth_ref": [], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Patents, net" } } }, "localname": "PatentsNet", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ueec_PatentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Patents" } } }, "localname": "PatentsPolicyTextBlock", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ueec_PaymentsOfCompensation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payment of compensation" } } }, "localname": "PaymentsOfCompensation", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_ProceedsFromConvertibleNotesPayableRelatedParty": { "auth_ref": [], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Proceeds from convertible notes payable]", "negatedLabel": "Proceeds from convertible notes payable" } } }, "localname": "ProceedsFromConvertibleNotesPayableRelatedParty", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_PromissoryNotePayabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Promissory Note Payable]", "verboseLabel": "Promissory Note Payable" } } }, "localname": "PromissoryNotePayabletextblock", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/PromissoryNotePayable" ], "xbrltype": "textBlockItemType" }, "ueec_RelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party [Member]" } } }, "localname": "RelatedPartyMember", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_RemainingBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Remaining balance" } } }, "localname": "RemainingBalance", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_RestrictedStockUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted stock units granted", "verboseLabel": "Restricted stock units granted" } } }, "localname": "RestrictedStockUnits", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ueec_RestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted Stock Units [Member]" } } }, "localname": "RestrictedStockUnitsMember", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_RestrictedStockUnitsVesting": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising.", "label": "Restricted stock units, vesting" } } }, "localname": "RestrictedStockUnitsVesting", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ueec_RsuGrantedToOfficersDirectorsAndConsultants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RSU granted to officers, directors and consultants" } } }, "localname": "RsuGrantedToOfficersDirectorsAndConsultants", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ueec_SaleOfCommonStockAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Sale of common stock, amount" } } }, "localname": "SaleOfCommonStockAmount", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_SaleOfCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sale of common stock, shares" } } }, "localname": "SaleOfCommonStockShares", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ueec_SeriesAConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Convertible Preferred Stock [Member]" } } }, "localname": "SeriesAConvertiblePreferredStockMember", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "ueec_SharesIssuedForSettelAccruedLiabilityAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issued for settel accrued liability, amount" } } }, "localname": "SharesIssuedForSettelAccruedLiabilityAmount", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_SharesIssuedForSettelAccruedLiabilityShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares issued for settel accrued liability, shares" } } }, "localname": "SharesIssuedForSettelAccruedLiabilityShares", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ueec_StockBasedCompensationExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Stock-based compensation expense" } } }, "localname": "StockBasedCompensationExpense", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_Thereafter": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Thereafter" } } }, "localname": "Thereafter", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "ueec_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average number of shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDiluted", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" }, "ueec_WeightedAverageTotalAwardsOutstandingBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average total awards outstanding, beginning" } } }, "localname": "WeightedAverageTotalAwardsOutstandingBeginning", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetails" ], "xbrltype": "stringItemType" }, "ueec_WeightedAverageTotalAwardsOutstandingEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average total awards outstanding, ending" } } }, "localname": "WeightedAverageTotalAwardsOutstandingEnding", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetails" ], "xbrltype": "stringItemType" }, "ueec_WeightedAverageUnitsCancelledForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average units cancelled/forfeited" } } }, "localname": "WeightedAverageUnitsCancelledForfeited", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetails" ], "xbrltype": "stringItemType" }, "ueec_WeightedAverageUnitsExercisedReleased": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average units exercised/released" } } }, "localname": "WeightedAverageUnitsExercisedReleased", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetails" ], "xbrltype": "stringItemType" }, "ueec_WeightedAverageUnitsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average units granted" } } }, "localname": "WeightedAverageUnitsGranted", "nsuri": "http://unitedhealthproductsinc.com/20220331", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r23" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableInterestBearingCurrent": { "auth_ref": [ "r22", "r211", "r212", "r214" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable to vendors that bear interest at either a stated or an imputed rate. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued interest" } } }, "localname": "AccountsPayableInterestBearingCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r7", "r8", "r25" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued compensation", "verboseLabel": "Accrued interest" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued liabilities - related parties" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r7", "r8", "r25" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued", "verboseLabel": "Accrued" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/LitigationDetailsNarrative", "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r7", "r8", "r25" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Civil penalty accrue" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r14", "r184", "r225" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "[Additional Paid in Capital]", "verboseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r73", "r74", "r75", "r181", "r182", "r183", "r199" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "verboseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile net (loss) to Net Cash Used In Operating Activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r46", "r59", "r162", "r211" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Potential antidilutive shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_AssetRetirementObligationAccretionExpense": { "auth_ref": [ "r142", "r143" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accretion expense recognized during the period that is associated with an asset retirement obligation. Accretion expense measures and incorporates changes due to the passage of time into the carrying amount of the liability.", "label": "Stock based compensation expense" } } }, "localname": "AssetRetirementObligationAccretionExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r71", "r109", "r112", "r118", "r133", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r191", "r195", "r202", "r223", "r225", "r244", "r252" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r32", "r71", "r133", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r191", "r195", "r202", "r223", "r225" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets, Current]", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r176", "r180" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date Axis" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative", "http://unitedhealthproductsinc.com/role/OtherIncomeDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative", "http://unitedhealthproductsinc.com/role/OtherIncomeDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r3", "r72", "r105" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "verboseLabel": "Organization and Basis of Preparation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/OrganizationAndBasisOfPreparation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r21", "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "[Cash and Cash Equivalents, at Carrying Value]", "periodEndLabel": "CASH AND CASH EQUIVALENTS - END OF PERIOD", "periodStartLabel": "Cash and Cash Equivalents - Beginning of period" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r9", "r62" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r54", "r203" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect]", "totalLabel": "Increase in Cash and Cash Equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r21" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash Investing & Financing Activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Information by type of borrower determined on the basis of initial measurement attribute, risk characteristics and method of monitoring and assessing credit risk.", "label": "Class Of Financing Receivable Type Of Borrower Axis" } } }, "localname": "ClassOfFinancingReceivableTypeOfBorrowerAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Category of entity or individual who borrows funds." } } }, "localname": "ClassOfFinancingReceivableTypeOfBorrowerDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r70", "r71", "r86", "r87", "r88", "r90", "r91", "r95", "r96", "r97", "r133", "r148", "r152", "r153", "r154", "r157", "r158", "r165", "r166", "r167", "r168", "r202", "r270" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical", "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r29", "r144", "r247", "r257" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockDividendsShares": { "auth_ref": [ "r169" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits.", "label": "Common stock sold" } } }, "localname": "CommonStockDividendsShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r73", "r74", "r199" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, shares par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued", "verboseLabel": "Common stock shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical", "http://unitedhealthproductsinc.com/role/LitigationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r13", "r169" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r13", "r225" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock - $.001 par value, 300,000,000 shares Authorized, 228,877,509 and 228,667,229 shares issued at March 31, 2022 and December 31, 2021" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetSale": { "auth_ref": [ "r135" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease from sale of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time and other income.", "label": "Common stock with a fair value" } } }, "localname": "ContractWithCustomerAssetSale", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r64", "r65", "r66" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "[Conversion of Stock, Shares Issued]", "verboseLabel": "Common stock issued for conversion of convertible notes payable and accrued interest - related party, shares" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r10", "r245", "r253", "r265" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Converted loans payable and accrued liabilities" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r25" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible loans payable - related parties" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r44", "r229" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Reimbursable expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Promissory Note Payable (Details Narrative)" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": { "auth_ref": [ "r171" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.", "label": "Beneficial conversion feature" } } }, "localname": "DebtInstrumentConvertibleBeneficialConversionFeature", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r27", "r161", "r212" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Interest Rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r28", "r159", "r201" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Maturity Date", "verboseLabel": "Maturity Date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuances of Securities (Details)" } } }, "localname": "DebtSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r59", "r140" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Amortization expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss per common share:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r92", "r93" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Per Share Information" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r35", "r36", "r37", "r73", "r74", "r75", "r77", "r82", "r84", "r94", "r134", "r169", "r172", "r181", "r182", "r183", "r188", "r189", "r199", "r204", "r205", "r206", "r207", "r208", "r209", "r260", "r261", "r262", "r272" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ExplorationExpense": { "auth_ref": [ "r235" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Exploration expenses (including prospecting) related to oil and gas producing entities and would be included in operating expenses of that entity. Costs incurred in identifying areas that may warrant examination and in examining specific areas that are considered to have prospects of containing oil and gas reserves, including costs of drilling exploratory wells and exploratory-type stratigraphic test wells. Exploration costs may be incurred both before acquiring the related property (sometimes referred to in part as prospecting costs) and after acquiring the property. Principal types of exploration costs, which include depreciation and applicable operating costs of support equipment and facilities and other costs of exploration activities, are: (i) Costs of topographical, geographical and geophysical studies, rights of access to properties to conduct those studies, and salaries and other expenses of geologists, geophysical crews, and others conducting those studies. Collectively, these are sometimes referred to as geological and geophysical or \"G&G\" costs. (ii) Costs of carrying and retaining undeveloped properties, such as delay rentals, ad valorem taxes on properties, legal costs for title defense, and the maintenance of land and lease records. (iii) Dry hole contributions and bottom hole contributions. (iv) Costs of drilling and equipping exploratory wells. (v) Costs of drilling exploratory-type stratigraphic test wells.", "label": "[Exploration Expense]", "verboseLabel": "Amortization expense" } } }, "localname": "ExplorationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r138" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2022 (remaining)" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r138" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r138" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r138" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r138" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfDebtInvestments": { "auth_ref": [ "r59" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The difference between the carrying value and the sale price of debt securities, not separately or otherwise categorized as trading, available-for-sale, or held-to-maturity. This element refers to the gain (loss) included in earnings and not to the cash proceeds of the sale.", "label": "[Gain (Loss) on Sale of Debt Investments]", "verboseLabel": "Loss on settlement of debt" } } }, "localname": "GainLossOnSaleOfDebtInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r59", "r163", "r164" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 9.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Loss on settlement of debt", "negatedLabel": "Loss on settlement of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited", "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r43", "r71", "r109", "r111", "r114", "r117", "r119", "r133", "r148", "r149", "r150", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r202" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 7.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "[Gross Profit]", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r139", "r141" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment of Long-lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Statements of Operations (Unaudited)" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r56", "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r58" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "[Increase (Decrease) in Accounts Payable and Accrued Liabilities]", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInCustomerAdvances": { "auth_ref": [ "r58" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of prepayments by customers for goods or services to be provided at a later date.", "label": "Received in advanced" } } }, "localname": "IncreaseDecreaseInCustomerAdvances", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent": { "auth_ref": [ "r58" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Accrued liabilities - related party" } } }, "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r58" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "[Increase (Decrease) in Inventories]", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r58" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "[Increase (Decrease) in Other Current Assets]", "negatedLabel": "Prepaid and other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r38", "r108", "r210", "r213", "r249" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 11.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "[Interest Expense]", "negatedLabel": "Interest expense", "verboseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited", "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseRelatedParty": { "auth_ref": [], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 10.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.", "label": "[Interest Expense, Related Party]", "negatedLabel": "Interest expense - related party" } } }, "localname": "InterestExpenseRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r52", "r55", "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentInterestRate": { "auth_ref": [ "r131", "r132" ], "lang": { "en-us": { "role": { "documentation": "Rate of interest on investment.", "label": "Accrues interest" } } }, "localname": "InvestmentInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuances of Securities" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "verboseLabel": "Litigation" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/Litigation" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r24", "r71", "r113", "r133", "r148", "r149", "r150", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r192", "r195", "r196", "r202", "r223", "r224" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "[Liabilities]", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r18", "r71", "r133", "r202", "r225", "r246", "r256" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "[Liabilities and Equity]", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r26", "r71", "r133", "r148", "r149", "r150", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r192", "r195", "r196", "r202", "r223", "r224", "r225" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "[Liabilities, Current]", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayable": { "auth_ref": [ "r10", "r245", "r251" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Loans payable - related parties" } } }, "localname": "LoansPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesSought": { "auth_ref": [ "r144", "r145", "r146" ], "lang": { "en-us": { "role": { "documentation": "Describes the form and magnitude of the award the plaintiff seeks in the legal matter, which may include an unspecified amount of money.", "label": "Loss contingency damages sought, description" } } }, "localname": "LossContingencyDamagesSought", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/LitigationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r144", "r145", "r146" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Compensatory damages" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/LitigationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r54" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 18.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "[Net Cash Provided by (Used in) Financing Activities]", "totalLabel": "Cash flow provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r54" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 19.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "[Net Cash Provided by (Used in) Investing Activities]", "totalLabel": "Net Cash Used in Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r54", "r57", "r60" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 20.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "totalLabel": "Net Cash Used In Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r33", "r34", "r37", "r40", "r60", "r71", "r76", "r78", "r79", "r80", "r81", "r83", "r84", "r89", "r109", "r111", "r114", "r117", "r119", "r133", "r148", "r149", "r150", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r200", "r202", "r248", "r258" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net Income (Loss) Attributable to Parent]", "totalLabel": "Net Income/(Loss)", "verboseLabel": "Net Loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited", "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r10", "r245", "r254" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Promissory note payable", "verboseLabel": "Promissory note payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets", "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingCostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Costs and Expenses" } } }, "localname": "OperatingCostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 6.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "[Operating Expenses]", "totalLabel": "Total Operating Expenses", "verboseLabel": "Operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r109", "r111", "r114", "r117", "r119" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "[Operating Income (Loss)]", "totalLabel": "Income/(Loss) from Operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Basis of Preparation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r259" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 8.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other income", "verboseLabel": "Other income" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited", "http://unitedhealthproductsinc.com/role/OtherIncomeDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense)" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r173", "r185" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "verboseLabel": "Other income" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/OtherIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r47" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "[Other Nonoperating Income (Expense)]", "totalLabel": "Total other income (expense)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation (Details Narrative)" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "auth_ref": [ "r48" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "[Payments to Acquire Short-term Investments]", "negatedLabel": "Purchase of intangible assets" } } }, "localname": "PaymentsToAcquireShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r12", "r165" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, shares par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r12", "r165" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r12", "r225" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Series A Convertible Preferred Stock - $.001 par value, 1,000,000 shares Authorized and 0 shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r5", "r19", "r20" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r49" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from sale of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r50" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from related party", "terseLabel": "Related party advances", "verboseLabel": "Loan from related party" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited", "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r33", "r34", "r37", "r53", "r71", "r76", "r83", "r84", "r109", "r111", "r114", "r117", "r119", "r133", "r148", "r149", "r150", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r190", "r193", "r194", "r197", "r198", "r200", "r202", "r250" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]", "negatedLabel": "Net (Loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r41", "r136" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Bad debt expense" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r174", "r217", "r218" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/LitigationDetailsNarrative", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r174", "r217", "r218", "r220" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction Axis" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://unitedhealthproductsinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://unitedhealthproductsinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r174", "r217", "r220", "r231", "r232", "r233", "r234", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party Axis" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/LitigationDetailsNarrative", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r215", "r216", "r218", "r221", "r222" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "verboseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r51" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Monthly payments" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r51" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "[Repayments of Notes Payable]", "negatedLabel": "Repayments on loan payable", "verboseLabel": "Repayments on loan payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited", "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r186", "r228", "r266" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r15", "r172", "r184", "r225", "r255", "r263", "r264" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "[Retained Earnings (Accumulated Deficit)]", "verboseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r73", "r74", "r75", "r77", "r82", "r84", "r134", "r181", "r182", "r183", "r188", "r189", "r199", "r260", "r262" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "verboseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r68", "r69" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r39", "r71", "r106", "r107", "r110", "r115", "r116", "r120", "r121", "r122", "r133", "r148", "r149", "r150", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r202", "r250" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAmortizationExpensePerUnitOfProductionTextBlock": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of amortization expense per unit of production for oil and gas enterprises that follow the full cost method of accounting for investments in oil and gas properties.", "label": "Schedule of Future Amortization Expense" } } }, "localname": "ScheduleOfAmortizationExpensePerUnitOfProductionTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in restricted stock units (RSUs).", "label": "Schedule of Restricted stock units" } } }, "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r45" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r58" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock for services and compensation", "verboseLabel": "Stock based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Number of units granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r176", "r177" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r169" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r67", "r72" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r11", "r12", "r13", "r70", "r71", "r86", "r87", "r88", "r90", "r91", "r95", "r96", "r97", "r133", "r148", "r152", "r153", "r154", "r157", "r158", "r165", "r166", "r167", "r168", "r169", "r202", "r270" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Statement Class Of Stock Axis" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical", "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r31", "r35", "r36", "r37", "r73", "r74", "r75", "r77", "r82", "r84", "r94", "r134", "r169", "r172", "r181", "r182", "r183", "r188", "r189", "r199", "r204", "r205", "r206", "r207", "r208", "r209", "r260", "r261", "r262", "r272" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical", "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited", "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative", "http://unitedhealthproductsinc.com/role/LitigationDetailsNarrative", "http://unitedhealthproductsinc.com/role/OtherIncomeDetailsNarrative", "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://unitedhealthproductsinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Statements of Cash Flows (Unaudited)" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Balance Sheets" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Statement of Stockholders Equity (Unaudited)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r73", "r74", "r75", "r94", "r229" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical", "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited", "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative", "http://unitedhealthproductsinc.com/role/LitigationDetailsNarrative", "http://unitedhealthproductsinc.com/role/OtherIncomeDetailsNarrative", "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://unitedhealthproductsinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r30", "r160", "r169", "r170", "r172" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Common stock issued for conversion of convertible notes payable and accrued interest, shares", "verboseLabel": "Debt instrument, conversion of shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited", "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Common stock, shares issued for service rendered, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r12", "r13", "r169", "r172" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Common stock shares issued during the period", "verboseLabel": "Common shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative", "http://unitedhealthproductsinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r12", "r13", "r169", "r172" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Stock-based compensation, shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r31", "r169", "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Common stock issued for conversion of convertible notes payable and accrued interest, amount" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Common stock, shares issued for service rendered, amount" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r12", "r13", "r172", "r175", "r179" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock-based compensation, amount" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r13", "r16", "r17", "r71", "r129", "r133", "r202", "r225" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "[Stockholders' Equity Attributable to Parent]", "periodEndLabel": "Balance, amount", "periodStartLabel": "Balance, amount", "totalLabel": "Total Stockholders' Equity (Deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets", "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity (Deficit)" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Event" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/SubsequentEvent" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock Axis" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Going Concern" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r124", "r125", "r126", "r127", "r128", "r130" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Trade Accounts Receivable and Concentration Risk" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r187" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized compensation cost" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r98", "r99", "r100", "r101", "r102", "r103", "r104" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.", "label": "Restricted stock unit, vested" } } }, "localname": "WeightedAverageNumberOfSharesRestrictedStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r105": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r147": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r173": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "http://asc.fasb.org/topic&trid=49130413" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r185": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "http://asc.fasb.org/topic&trid=2122503" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=51888271" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r222": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r227": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10.(c)(7)(i))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62136-109447" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16)(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r267": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r268": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r269": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r271": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r72": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2646-109256" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" } }, "version": "2.1" } ZIP 45 0001477932-22-003316-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-22-003316-xbrl.zip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¯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end